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ABSTRACT 
 
Influenza viruses, although common, cause thousands of deaths worldwide and remain a 
prominent public health issue, especially with the growing population of elderly and immune-
compromised individuals.  Currently, the influenza vaccine is the best tool available at protecting 
against infection, but the correct strains are hard to predict and the vaccines do not always work.  
Therefore, it is necessary to explore more effective antiviral drugs.  New antivirals like these are 
of public health importance because they can help reduce morbidity and mortality related to 
influenza infection.  Our collaborators from the University of Washington have computationally 
designed a small protein, HB36.6, which interferes with influenza infection by binding the virus’ 
hemagglutinin surface protein.  This thesis has tested the novel antiviral using the influenza 
A/California/07/09 (H1N1) strain in a ferret model by looking at the effects of low and high 
doses of HB36.6, and comparing it to untreated controls or against the current standard antiviral, 
Tamiflu.  Antiviral effectiveness was evaluated using a combination of clinical and viral 
parameters.  First, the animals were monitored and scored using a detailed clinical scoring 
system for onset of clinical signs of disease, as well as tracked through daily measurements of 
weights and temperatures.  Second, viral titers were quantitated using RT-PCR in tissue samples 
obtained at necropsy and the untreated controls were compared to HB36.6-treated animals or 
those treated with Tamiflu.  The overall hypothesis for this study was that HB36.6 will be 
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effective in reducing viral loads and limiting disease following aerosolized influenza infection in 
the ferret model, and this reduction in viral loads/disease would be more effective than the 
currently used antiviral, Tamiflu.  The results of these studies show that HB36.6-treated animals 
display fewer clinical symptoms when a low dose of the treatment is used, but there appears to 
be no reduction in viral loads.  Higher doses appear to be toxic to the animals, especially when 
taken over multiple days throughout the course of infection. These studies have yielded 
important information on a new class of influenza therapeutics that should be further evaluated 
using larger sample sizes.  
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1.0  INTRODUCTION 
Influenza is a negative-sense, single-stranded RNA virus consisting of three subtypes, A, 
B, and C.  These viruses contain 8 segments that code for 11 or 12 proteins.  Influenza virus is 
the only virus within the family Orthomyxoviridae that can cause infection in humans.  Influenza 
A virus is the most virulent and can cause serious disease in humans, as well as birds and other 
mammals, while humans remain the only natural reservoir for Influenza B [1, 2].  Influenza 
viruses are classified according to their surface proteins, hemagglutinin (HA) and neuraminidase 
(NA).  NA, a glycoprotein that cleaves sialic acid from host cell membranes to increase the 
likelihood of viral release, is highly conserved among influenza strains [3].  HA mediates viral 
binding to their target cells through recognition of the terminal sialic acid residues [4].  Influenza 
viruses are categorized into two phylogenic groups, which consist of 18 HA and 11 NA 
identified subtypes [5, 6].  Avian and swine Influenza A viruses are of great interest to 
researchers because of these animals proximity to humans (livestock and household pets), and 
therefore, opportunities to allow the disease to mutate and spread.  Together, these viruses cause 
an average of 250,000-500,000 deaths annually around the world and infect 5-20% of the US 
population [1, 2, 5].  HA and NA periodically undergo antigenic drift (minor changes such as 
point mutations in the RNA gene segments), resulting in redirection of the immune response.  
Antigenic shift takes place when a host is infected with two different viruses and there is 
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reassortment of gene segments during viral replication, creating a new virus strain, which can 
cause pandemics [1, 2].   
Influenza A viruses primarily target epithelial cells in the upper and lower respiratory 
tracts during infection, as the HA surface proteins bind to exposed sialic acid residue 
glycoproteins on the surface of respiratory epithelial cells. This protease-mediated cleavage 
promotes viral entry by activating endocytosis of the virus.  A low pH in the endosome allows 
for uncoating of the virion so that it may undergo viral replication.  Following viral replication, 
progeny are transported to the cell membrane to once again bind the sialic acid residues via NA. 
This time, the linking promotes viral release, so that the virus may move on to infect more cells 
[2].  Influenza infection, like many other diseases, causes an inflammatory response in the body, 
which activates both innate and adaptive immune responses.  Normal response stages to 
inflammation include, “(i) recognition of the problem, (ii) recruitment of leukocytes and other 
immune system components, (iii) elimination of the threat, and (iv) resolution of the 
inflammatory state (i.e., a return to homeostasis)” [7]. 
In 2009, a novel influenza A H1N1 caused the first pandemic of this century as a strain 
with mixed avian, swine and human IV genes from North American and Eurasian swine 
influenza virus lineages.  Compared to seasonal influenza, this pandemic strain is highly 
pathogenic with considerably more viral replication in the upper respiratory tract [8].  Today, the 
A(H1N1)pdm09 strain can still cause mild to severe disease resulting in hospitalization and 
mortality, and therefore remains a prominent public health issue [1]. 
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1.1 BURDEN AND EPIDEMIOLOGY 
To predict the next seasonal influenza strains, scientists watch the Southern Hemisphere 
countries, like New Zealand, where influenza season occurs between June and September.  After 
the 2009 influenza pandemic, the US Department of Health and Human Services, Centers for 
Disease Control and Prevention (CDC) funded the Southern Hemisphere Influenza and Vaccine 
Effectiveness Research and Surveillance (SHIVERS) project to take place over five years, from 
2012-2016, in New Zealand.  The goal of this project is to measure influenza burden, 
epidemiology, etiology, risk factors, immunology, effectiveness of vaccination, and other 
prevention strategies for influenza.  In the first year of the study, the overall adjusted annual 
incidence rate of hospitalization due to influenza was 54/100,000 persons, which is similar to US 
data from 1979-2001 showing an average annual incidence of 36.8/100,000 persons.  It also 
confirmed that the very young (≤4 years), elderly (≥65), and the most deprived socio-economic 
status (SES) groups have the highest rates of influenza-associated hospitalizations [9].   
Severe acute respiratory illness (SARI) surveillance often underestimates the true burden 
of influenza-associated hospitalizations and mortalities due to patients not meeting the case 
definition, or being incorrectly diagnosed, tested, and recorded as having influenza.  When a 
patient dies of a secondary bacterial infection or exacerbation of a pre-existing condition, this is 
what is recorded on the death certificate.  SHIVERS data on influenza-like illness (ILI) is used to 
measure disease burden of moderate influenza disease.  These data show that preschool children 
(1-4 years), school-age children, adults (<65 years), people of Asian ethnicity, and those of lower 
SES are at greatest risk of developing ILI-associated influenza [9].  In the US, for the 2013-2014 
influenza season there were more than 105 influenza-related child deaths reported to the CDC 
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and the vaccine was determined to only be 62% effective against the most prominent virus strain, 
2009 H1N1 [10].   
1.2 THE FERRET MODEL 
Because of the impact of influenza viruses in the community, many researchers study the 
disease using animal models.  In order to better understand influenza A infection in humans, 
researchers have used various animal models, including mice, ferrets, cats, dogs, guinea pigs, 
and nonhuman primates.  Mice are one of the most commonly used models for influenza 
research because they are inexpensive, easy to house, easily accessible, and murine-specific 
immunologic reagents are widely available.  However, mice are not a natural host for influenza 
viruses, so the strains must be adapted for mouse studies.  Also, mice do not display clinical 
signs of disease in the same way as humans, and these signs can differ depending on the dose of 
virus administered [2].  
Ferrets, Mustela putorius furo, have been used in influenza research since the 1930s [2, 
5].  Their main advantages include a similar presentation of disease to human through observed 
clinical symptoms, they are naturally susceptible to human influenza viruses, and they can be 
used to study the different modes of influenza transmission [2].  Ferrets present similar clinical 
signs of disease as humans, including fever, nasal discharge, sneezing, and lethargy [2, 11].  
They are also small to intermediate in size, making them convenient to house and transport, and 
they prefer to be caged in same-sex groups.  In relation to smaller rodent models, ferrets can 
provide more sizable blood and tissue samples [5, 11].  The complete ferret genome and 
transcriptome can be found online to offer ways of comparing species-specific genes and 
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developing undiscovered signaling pathways.  Ferrets can even be used to demonstrate and 
predict the emergence of drug-resistant strains of influenza [5]. 
Ferrets also share similarities to humans in the respiratory tract, lung physiology, airway 
morphology, and metabolism [1, 5].  Influenza A virus (IAV) presents similarly in the ferret and 
human respiratory tract because they both have a similar distribution of sialic acid receptors in 
the trachea and lower respiratory tract [2, 8].  One main difference is that influenza infection in 
ferrets rarely progresses to pneumonia because the viruses manifest in the upper respiratory tract 
rather than the lower respiratory tract.  Ferrets are useful in vaccine research because they 
develop active immunity with neutralizing antibodies after being infected with human IAV 
strains [2].  Severity or fatality of disease can depend on the age of the host and the strain of 
virus [1].   
Some limitations of the ferret model include their increased expense over mice, their 
limited commercial availability, the requirement for more complex housing arrangements, and 
the limited availability of reagents [2].  Ferrets are now being offered as specific pathogen free 
(SPF) by some commercial breeders, where they pre-test animals for infectious disease before 
purchase.  However, due to the natural susceptibility of ferrets for human respiratory virus, it is 
highly recommended that individual laboratories confirm the serological status for disease of the 
ferrets prior to infection.  Currently, there is limited availability of ferret-specific immunological 
reagents.  Researchers are left to test and identify reagents from other species that may be cross-
reactive for the ferret.  Fortunately, using mRNA expression levels though quantitative real-time 
RT-PCR researchers are able to study innate immune responses in ferrets similarly to those seen 
in human patients [5].   Therefore, despite these limitations, ferrets remain an important model 
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for influenza research as they can provide a form of active surveillance on the pathogenicity and 
virulence of new strains. 
1.3 INFLUENZA PREVENTION AND TREATMENT 
Influenza virus is contagious, and spread of the disease can occur through direct contact 
with an infected individual, indirect contact with an inanimate object that carries germs from the 
infected individual, or through airborne transmission (coughing, sneezing) [2, 12].  Typical 
clinical symptoms of the pandemic 2009 A(H1N1) and seasonal A(H1N1) virus include fever, 
sneezing, coughing, headache, muscle aches, and sore throat, which make them hard to 
distinguish from one another [2, 8, 12].  The risk of influenza or influenza-associated 
complications is highest among children, the elderly, pregnant women, and people with other 
health conditions like heart disease or weakened immune systems [12].  
1.3.1 Vaccines 
The best protection against seasonal influenza is the vaccine, which can help prevent the 
spread of disease from person to person.  The CDC recommends all eligible people receive the 
vaccine annually, and children 6 months to 8 years of age may receive two doses.  Each year, the 
influenza vaccine is created to protect against three (trivalent) or four (quadrivalent) of the most 
prominent strains that are most likely to cause disease as predicted through surveillance [12].  
The vaccine works by triggering an immune response in the body to produce antibodies and T 
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cells to fight off the infection [13].  After a person receives the vaccine, it takes approximately 
two weeks for protection to develop against influenza [12]. 
Influenza vaccines are time-consuming to make and require the expertise from people in 
many fields, including microbiology, epidemiology, and veterinary [13].  Each year, the World 
Health Organization consults with experts to decide which strains of influenza are likely to 
circulate the following year and should be placed in the vaccines.  Vaccine strains are chosen 
using past viral strains, and therefore antigenic shift and drift are impossible to anticipate [2].  
Influenza vaccines are produced by private manufacturers who are approved and licensed by the 
U.S. Food and Drug Administration (FDA).  Manufacturers approved for the 2015-16 influenza 
season included GlaxoSmithKline, ID Biomedical Corporation of Quebec (distributed by 
GlaxoSmithKline), Sanofi Pasteur, bioCSL, Novartis Vaccines and Diagnostics, Protein 
Sciences, and MedImmune.  Vaccines differ by production type, dose, and number of strains 
[12]. 
There are two types of vaccines available to protect against influenza, the Inactivated 
Influenza Vaccine (IIV) and the Live Attenuated Intranasal Vaccine (LAIV).  IIV does not 
contain any live virus and is given through intramuscular injection with a needle.  IIV viruses are 
inactivated by chemicals, such as beta-Propiolactone (BPL) or formaldehyde [14], or through 
inactivation with heat, ultraviolet light, or gamma rays [15].  LAIV is administered intranasally 
as a spray and contains a weakened live virus [12].  LAIV viruses are attenuated using heat; they 
cannot grow well in a host, but replicate enough to elicit an immune response.  The vaccine virus 
is only able to cause infection in cooler temperatures, such as those found in the nose; they 
cannot infect warmer areas of the body such as the lungs [16].  The U.S. FDA approves private 
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sector manufacturers to make vaccines using various methods, including egg-based, cell-based, 
and recombinant influenza vaccines [16].   
Traditionally, influenza vaccines are egg-based and viruses are grown in millions of 
fertilized chicken embryos.  The virus is injected into the egg and allowed to incubate for several 
days so that the virus can multiply.  The virus is harvested and put through a purification process 
where the manufacturer and FDA test the virus for potency and safety.  Once approved, the 
different strains produced for that year are mixed together and standard doses are placed in 
containers including vials, syringes and nasal sprayers where it undergoes more quality control 
tests, such as for sterility.  A sample of each lot and results are sent to the FDA, which confirms 
the results and allows the manufacturer to begin shipping the vaccines throughout the US.  This 
process takes approximately 6 months from start to completion [13]. 
In 2010, the FDA pushed to find an easier and faster way to make influenza vaccines 
using cell culture technology, and by 2012 had approved cell-based influenza vaccines that use 
mammalian cell lines [13, 16].  Cell-based vaccines also begin with egg-grown virus.  Instead of 
incubating the virus in eggs, it is cultured using Madin-Darby Canine Kidney (MDCK) cells and 
allowed to replicate.  The virus is harvested from the MDCK cells, purified, and undergoes the 
same testing as egg-based vaccines [16].  The FDA believed that this advancement would help 
the US respond to public health emergencies in a timely manner.  Advantages of this new cell 
technology include the ability to freeze the cells for later use, not relying on the availability of 
eggs for production, and potentially growing better viruses at a quicker rate [13].   
The latest vaccine production type was approved in 2013.  Unlike egg-based and cell-
based vaccines, recombinant technology allows for the production of virus without using egg-
grown virus or eggs in the production process.  Instead, these “recombinant” vaccines use a 
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protein isolate, like HA, from the recommended circulating virus strain.  The isolate is then 
combined with a virus that grows well in insect cells, mixed with those cells, and allowed to 
replicate.  The influenza protein isolate (HA) is then harvested from the insect cells and purified 
before placement in the egg-free vaccine.  This method is the only FDA approved egg-free 
method, and currently only one vaccine is available in the U.S.  It is the quickest method because 
it does not depend on an egg supply [16].   
Influenza viruses are constantly evolving, utilizing antigenic shift and drift, which is why 
a new vaccine is required every year.  Scientists around the globe are constantly working to 
collect influenza samples to try to identify which strains will most likely be circulating during 
the next influenza season.  One inherent problem with influenza vaccines is the need for the FDA 
to make its recommendation on which strains should go into the vaccine for the upcoming 
influenza season each year.  The strains must be decided well in advance of the influenza season 
so that various manufacturers using different technologies can begin to make the vaccine for the 
fall [13].  Since the current influenza season has not ended when strain selection occurs, it is 
possible to choose the incorrect strains to be placed in the following year’s vaccine.  IIV and 
LAIV have both been proven to be effective in children and adults, and for the 2015-16 season 
the Advisory Committee on Immunization Practices does not recommended one over the other.  
However, there are certain groups of people who are recommended to not receive the LAIV, 
including those aged <2 or >49 years, pregnant women, immunocompromised individuals, and 
individuals with other certain health conditions.  Efficacy of the vaccine depends on the 
characteristics of the person receiving the vaccine (age and current health-status) and whether the 
selected vaccine strains are a good fit for what is circulating that year.  For the 2014-15 influenza 
season, laboratory analysis determined that the selected influenza A strains were antigenically or 
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genetically different from the strains that were circulating in the environment, resulting in 
reduced effectiveness of the vaccine [16].  When this occurs, it is pertinent to have good antiviral 
drugs available to help reduce the effects of an infection. 
1.3.2 Antivirals 
When the influenza vaccine fails, the community must then rely on antiviral drugs to help 
combat influenza infection.  Antiviral therapy is recommended for those with severe disease or 
who are at-risk of contracting severe disease, including the elderly, pregnant women, and people 
with autoimmune disorders [2].  Researchers use the virus life cycle to study influenza and 
determine new ways to block infection.  Currently, there are two classes of antivirals on the 
market to protect against influenza, matrix 2 (M2) channel inhibitors and neuraminidase (NA) 
inhibitors [3, 5]. 
There are two M2 ion channel blockers on the market, amantadine (Symmetrel, Endo 
Pharmaceuticals) and rimantadine (Flumadine, Forest Pharmaceuticals).  M2 ion channel 
proteins are transmembrane proteins that form proton ion channels across the viral membrane.  
These proteins transport protons from the late endosome into the interior of the virus.  
Acidification resulting from this transfer induces a hemagglutinin conformation change so that 
the virus can fuse and infect host cells by releasing the viral RNA into the cytoplasm.  M2 ion 
channel blockers bind the interior of the ion channel, blocking proton transport, and preventing 
the hemagglutinin conformation change that allows membrane fusion [17].  Adamantane 
antivirals only protect against influenza A.  The FDA does not typically recommend these drugs 
because there have been high levels of antiviral resistance in the last few influenza seasons, 
while resistance against oseltamivir, zanamivir, and peramivir is still low [10, 12]. 
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In the US during the 2014-2015 influenza season, there were three FDA-approved NA 
inhibitors available to treat or prevent disease from influenza A and B viruses: oseltamivir 
(Tamiflu, Roche), zanamivir (Relenza, GlaxoSmithKline), and peramivir (Rapivab, 
BioCryst) [10, 17].  NA is a surface protein on the viral envelope that consists of four identical 
subunits.  Its main role is to assist with viral progeny release from the infected cells.  This is 
achieved by cleaving the glycosidic bond between the other major glycoprotein, hemagglutinin, 
and the terminal sialic acid receptors of the host cell.  NA also assists with the break down of 
mucus in the respiratory tract, making it easier for the virus to attach to respiratory epithelium 
[18].  NA inhibitor antiviral drugs target the NA enzyme active site, located in the center of each 
subunit, which contain a number of highly conserved amino acid residues [19].  These drugs 
reduce infection by competing for NA binding and preventing progeny release of the virus from 
infected cells.  Oseltamivir and zanamivir remain the most widely-used treatment against 
influenzas A and B and can reduce the duration of symptoms from about 1 to 3 days if 
administered within 48 hours of symptom onset [2]. 
Prospective future recommended treatments include laninamivir, a newer NA inhibitor, 
and favivirapir, a nucleoside mimic that inhibits viral RNA-dependent RNA polymerase, that can 
inhibit common oseltamivir-resistant strains of influenza virus.  Fludase acts like NA, but 
destroys the host cell sialic acid receptors, leaving the virus with nothing to bind.  There are also 
experimental drugs aimed at blocking the hemagglutinin protein, including an Entry Blocker 
(EB) peptide that binds HA to exhibit broad-spectrum antiviral activity, and peptide NDFRSKT, 
which was discovered using an antiviral screening method [20]. 
One of the most popular prescription medications for treating influenza types A and B is 
oseltamivir, or Tamiflu.  Administration of Tamiflu through oral suspension is 6 mg/mL.  If 
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infection occurs, treatment should be taken twice daily for 5 days; if being used as a prophylaxis 
due to a community outbreak, treatment is once daily for 10 days up to 6 weeks [21].  The 
treatment must be used close to the time of infection in order for it to be effective [22].  Drug-
resistant mutations have emerged as variants of NA that bind and block oseltamivir from the 
active site.  Resistance to oseltamivir has spread from the pre-2009 pandemic H1N1 virus to 
encompass the 2009 pandemic virus [22].  During the U.S. 2013-14 influenza season, researchers 
from the Influenza Antiviral Working Group found that 59/4,968 (1.2%) of the predominant 
pandemic 2009 virus had the H275Y oseltamivir mutation that aids in antiviral resistance by 
decreasing NA stability [3, 23].  Only 15 of 49 (30.6%) of those patients with a resistant virus 
infection had received oseltamivir prior to sample collection.  Pennsylvania was one of the top 
states to provide oseltamivir-resistant virus specimens, 0/14 of which had exposure to 
oseltamivir prior to sample collection.  Before 2007, the number of NA-inhibitor-resistant 
viruses was low (<1%) due to fitness costs, but emergence of oseltamivir-resistant seasonal 
influenza A(H1N1) H275Y viruses began in the 2007-08 influenza season, and by 2008-09 were 
as high as 100% in some countries [3, 23].  This sharp increase is most likely due to an 
evolutionary advantage of H275Y variants, and is not attributed to oseltamivir use.  Researchers 
fear that the H275Y substitution may become fixed in the influenza A(H1N1)pdm09 viral 
genome as it did in the seasonal virus [23].  To counter this resistance, we need to develop new 
broad-spectrum treatments that will not result in virus resistance.  
Designing drugs that are less susceptible to antiviral resistance will be challenging and 
will depend upon highly integrated experimental and theoretical studies.  This field is likely to 
shift toward high-throughput screening that can help identify potential resistance-conferring 
mutations.  This selection process includes using random mutagenesis of codons or nucleotides 
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from more conserved genes like NA and HA in plasmids to create mutant libraries that are 
passaged through tissue culture with and without a drug.  Sequencing of each variant takes place 
before and after selection to determine the relative fitness.  Among its many significant findings, 
this process has revealed that HA has a high mutational tolerance [3].  
1.4 EXPERIMENTAL ANTIVIRAL PEPTIDE HB36.6 
Our collaborates from the University of Washington have developed a novel small 94 
amino acid protein, HB36.6, which is designed for use as a pre-exposure prophylactic and post-
exposure therapeutic against influenza virus.  Dr. David Baker created the peptide using his 
innovative computational modeling program (Rosetta).  He created the peptide to interfere with 
influenza infection by binding the highly conserved HA stem region, therefore neutralizing a 
wide range of influenza variants.  The peptide was optimized using deep mutational scanning, 
and was designed to interact similarly with seasonal, pandemic, and antiviral-resistant influenza 
strains.  It protects against human group 1 strains including H1N1 and H5N1.  The peptide has 
demonstrated a strong biopotency in vivo using intranasal delivery of the peptide in a mouse 
model and challenge with various group 1 influenza strains.  This peptide acts as a hemagglutinin 
inhibitor by targeting a neutralizing epitope on HA and inhibiting fusion of the virus with the 
host cell [6]. 
In the mouse model, a prophylactic dose of the peptide will specifically block infection at 
the mucosal site of exposure, while administration post-infection reduces disease and accelerates 
viral clearance.  The peptide binds directly to the virus without engaging a host receptor or 
invoking an immune response, and suppresses inflammatory (cytokine) responses associated 
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with influenza disease.  This peptide has proven to bind with equal or higher affinity than some 
monoclonal antibodies (mAbs), which also bind the HA stem to inhibit the conformational 
changes required for membrane fusion.  MAbs are a typical form of treatment in hospitals for 
critical influenza patients; they broadly bind and neutralize all group 1 influenza viruses in vitro.  
The new peptide does not protect against group 2 viruses because of the location of a glycan on 
the group 2 binding site that disrupts the binding pocket.  However, unlike mAbs these proteins 
lack an Fc, the critical component for its broad protective effects in vivo through its interaction 
with the FcγR [6]. 
Drs. Baker and Fuller began to reevaluate HB36.5 by constructing a library and using 
random mutagenesis of its nucleotides for selection against seven different group 1 HA subtypes 
[24].  The libraries were sequenced and the Baker laboratory computed the enrichment or 
depletion that accompanied each individual point mutation during affinity maturation.  A new 
library was then made consisting of the most optimal substitutions for all subtype selections at 12 
mutated positions and carried out several rounds of yeast display sorting against A/South 
Carolina/1/1918 (H1N1) HA, which developed into a variant with nine substitutions (HB36.6).  
Using negative-stain electron microscopy they confirmed that HB36.6 binds to the designed 
target location on the HA (Figure 1A-C), and biolayer interferometry showed the new peptide 
had high affinity (Figure 1D) and comparable equilibrium binding constants (Figure 1E) against 
all tested HA subtypes.  Compared to Ribavirin (a small molecule broad-spectrum antiviral 
approved in the US for treatment of Hepatitis C and Respiratory Syncytial Virus that neutralized 
influenza in vitro and protects against influenza virus in mice) and oseltamivir, HB36.6 
displayed stronger in vitro antiviral potency.  Co-treatments with oseltamivir and HB36.6 also 
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enhanced survival and lessened weight change in mice challenged with a lethal dose of influenza 
virus better than either antiviral treatment alone [6]. 
 
Figure 1. Characterization of HB36.6. 
(A) HA protein of A/South Carolina/1/1918 (H1N1). (B) PR8 HA bound to HB36.6. (C) HA protein from A/South 
Carolina/1/1918 (H1N1) (blue) with HB36.6 (cyan) docked into PR8 in B showing HB36.6 fits well into the stem 
region. (D) Equilibrium binding constants for HB36.5 and HB36.6 against various HAs demonstrated broad binding 
of group 1 subtypes. (E) EC50 (µg/ml) (compound concentration that reduces viral replication by 50%) of HB36.6, 
the monoclonal antibody FI6v3, and ribavirin against group 1 and group 2 viruses. ND = not determined [6].  
1.4.1 Preliminary Data 
The Fuller laboratory has shown that HB36.6 can block infection in Balb/c mice when 
administered prophylactically and reduces typical influenza symptoms while shortening disease 
when administered therapeutically at the mucosal site of exposure in vivo.  They found that when 
mice were given a pre-exposure high dose of 6 mg/kg or low dose of 0.01-3 mg/kg HB36.6 at 
≤48 hours before challenge with a lethal dose of mouse adapted H1N1 (A/California/07/2009), 
the treated mice showed 100% survival and less weight loss compared to untreated controls, 
which all died within 4-9 days post-infection (Figure 2A-B).  The afforded protection by HB36.6 
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was dependent on the intranasal (IN) route of antiviral delivery because the same antiviral dose 
administered intravenously (IV) was not protective.  HB36.6 was tested against other strains of 
influenza to see if results differed by strain (Figure 2C); results were similar amongst different 
strains.  To evaluate HB36.6 as a therapeutic, mice were treated IN after influenza exposure 
using either a single dose of 3 mg/kg HB36.6 given on day 0 (2 hours post infection), +1, +2, or 
+3 days PI, or the same dose administered daily on days +1-4 PI (Figure 2D).  When 
administered only once within 24 hours of infection, HB36.6 afforded a 60% survival rate, while 
administration daily after exposure afforded mice 100% survival with complete recovery in pre-
exposure weights [6]. 
 
 
Figure 2. HB36.6 protects against challenge with lethal dose of influenza virus in mice. 
Survival and weight change in (A) BALB/c mice treated with 6 mg/kg of HB36.6 at 2, 24, or 48 hours before 
challenge with 10 MLD50 CA09 H1N1 virus; (B) BALB/c mice treated with 0.01–3 mg/kg doses of HB36.6 2 hours 
before challenge with 10 MLD50 of CA09 virus; (C) BALB/c mice treated with 3 mg/kg of HB36.6 2 hours before 
infection with 10 MLD50 of CA09 virus or 6 MLD50 A/PR/8/34 (PR8) and (D) BALB/c mice treated with 3 mg/kg 
of HB36.6 on day 0 (2 hours post-infection) or +1, +2, or +3 days post-infection (d.p.i.), or once daily with HB36.6 
or control protein (sham, 1u84) on days +1-4 post-infection with 10 MLD50 CA09 virus.  Graphs are shown with 
mean with SEM [6]. 
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HB36.6-treated mice showed lower viral titers in nasal secretions and lung tissues on 
days 2, 4, and 6 PI (Figure 3A-B).  HB36.6 treatment (6 mg/kg) 24 hours before or 24 hours after 
lethal influenza challenge greatly suppressed the amounts of influenza-induced inflammatory 
cytokines (including IL-6, IL-10, IFN-g and TNF-α) detected in tissues at day 2 PI (Figure 3C).  
Antiviral cytokines were not detected in mouse lungs collected 24 hours after IN administration 
of HB36.6.  This shows that protection provided by HB36.6 is not linked to the induction of 
antiviral cytokines in the lungs.  After four weeks of treating mice biweekly with HB36.6, they 
were challenged with H1N1 to test the binder’s biopotency.  The binder did not induce 
antibodies in the weeks prior to influenza challenge and still provided 100% protection from 
mortality.  Protection was specific to HB36.6 binding to the HA because daily administration of 
the control scaffold protein (1u84) that HB36.6 is modeled on provided no protection [6]. 
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Figure 3. HB36.6 reduces viral replication and inflammation. 
(A) Nasal wash viral titers of untreated infected controls (Ctr) and mice that were treated with 6.0 mg/kg HB36.6 24 
hours before (Prophylaxis, Pro) or 24 hours after (Therapeutic, Ther) infection with 10 MLD50 CA09 influenza 
virus.  (B) Quantification of influenza positive cells in lung tissues performed by measuring the area of positive 
staining compared to the total tissue on the slide. (C) Inflammatory cytokines from lung homogenates obtained from 
BALB/c mice on day 2 post infection shown using the fold change over naïve-uninfected mice.  Significant 
differences between the Pro and Ther groups to the Ctr group are shown: *P < 0.05, **P < 0.001 [6]. 
HB36.6 shows promise as an effective antiviral in the mouse model.  Our lab has 
collaborated with the Fuller lab to further evaluate HB36.6 in the ferret model, a model that can 
afford evaluation of the peptide against influenza viruses without adaptation and that exhibits a 
disease course that more closely mimics humans.  Ultimately, the goal of these studies is to 
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broaden the antiviral efficiency to include protection from group 2 subtypes by combining a 
second small protein to work along with HB36.6.  This would allow the antiviral to protect from 
up to 16 different subtypes of influenza as well as drifted and shifted genetic variants of the 
virus.  Remaining uncertainty about host-pathogen interactions, vaccination, and lack of more 
efficient treatments limits our knowledge of influenza viruses [15].  These current studies seek to 
evaluate one new promising therapeutic candidate that will help to move the field closer to 
understanding these interactions, and hopefully identify a treatment that can move forward into 
humans. 
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2.0  STATEMENT OF THE PROJECT AND SPECIFIC AIMS 
Approximately 5-20% of the US population gets sick with influenza annually, and more 
than 200,000 people are hospitalized due to influenza-related complications [12]. Currently, the 
best protection against seasonal influenza is vaccination, but the correct strains are difficult to 
predict, and when predicted incorrectly, are less effective.  There are some prescription 
medications available to treat influenza, including oseltamivir (Tamiflu), a neuraminidase 
inhibitor, which was approved by the US Food and Drug Administration in 1999.  However, 
Tamiflu has received mixed reviews in its effectiveness to treat seasonal influenza [9].  Given the 
incident rate of influenza A, and the increasing number of elderly and immune compromised 
people around the globe, it is crucial to develop more effective ways of protecting these more 
vulnerable populations.   
This project is a combination of efforts from laboratories at the University of Washington 
and University of Pittsburgh, which seeks to test an antiviral drug, HB36.6, to protect against 
influenza A infection.  HB36.6 is a small protein that interferes with influenza infection by 
binding the virus’ hemagglutinin surface protein.  This peptide has proven to bind with equal or 
higher affinity than monoclonal antibodies, which are used as a form of treatment in hospitals for 
critical influenza patients.  Previous studies have determined HB36.6’s efficiency in the mouse 
model.  Mice are widely used in influenza studies, but they are not a natural host for influenza 
virus infection and cannot be naturally infected with human strains like ferrets [1, 11].  The ferret 
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was first discovered to be susceptible to human influenza in the 1930s and has since been widely 
used as a model for the disease [5].  The ferret is an appropriate model for influenza infection 
because it displays clinical signs of disease similarly to humans in that it produces fever, 
sneezing, generates nasal discharge, and exhibits lowered activity levels [11].  Our lab has now 
tested the antiviral’s effectiveness using the highly pathogenic influenza A H1N1 strain inside a 
ferret model.  These studies have yielded important information on a new class of influenza 
therapeutics that can be further evaluated in humans.  The overall hypothesis for this study was 
that HB36.6 would be effective in reducing viral loads and limiting disease following 
aerosolized influenza infection in the ferret model, and this reduction in viral loads/disease 
would be more effective compared to the currently used antiviral, Tamiflu. 
2.1 AIM 1: TO DETERMINE WHETHER TREATMENT WITH HB36.6 
RESULTS IN REDUCED CLINICAL SIGNS OF DISEASE COMPARED TO 
UNTREATED CONTROLS FOLLOWING AEROSOLIZED INFLUENZA 
INFECTION IN THE FERRET MODEL 
The ferrets were monitored and scored using a detailed clinical scoring system developed 
in collaboration with Dr. Fuller for onset of clinical signs of disease.  They were also tracked 
through daily measurements of weights and temperatures.  From these observations, we have 
determined the differences in physical indications of disease between each group of ferrets.  This 
aim was important in assessing the effectiveness of HB36.6. From these observations, results 
demonstrated less severe clinical disease in ferrets treated with HB36.6 compared to untreated 
controls. 
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2.2 AIM 2: TO DETERMINE WHETHER TREATMENT WITH HB36.6 
REDUCES VIRAL TITERS IN NASAL WASH AND LUNG TISSUE SAMPLES 
COMPARED TO UNTREATED CONTROLS FOLLOWING AEROSOLIZED 
INFLUENZA INFECTION IN THE FERRET MODEL 
Viral titers were determined through viral RNA extraction of nasal swab samples, 
followed by one-step quantitative real-time reverse-transcription PCR to evaluate samples 
collected at day 0 (pre-infection) through day 3 or 6-7 (necropsy took place on day 3 for study 
#2; day 6 for study #3; and day 6 or 7 for study #4).  Viral titers in lung samples were determined 
after viral RNA extraction followed by one-step quantitative real-time reverse-transcription PCR 
using tissues harvested at necropsy.  In many viral infections, viral titer is associated with 
severity of disease.  However, in influenza infection this is not always so clear.  It has been 
hypothesized that the immune response to influenza infection, often referred to as the “cytokine 
storm”, may contribute as much, if not more, to the pathogenesis of disease in influenza infection 
[25, 26].   
We further attempted to measure innate immune responses as reflected by cytokine 
responses in serum, nasal wash, and lung tissue samples.  Determination of the specific types and 
quantitation of each cytokine response produced in ferret samples after influenza infection was 
attempted using total RNA extraction followed by RT-PCR.  We hypothesized that If HB36.6 
was successful in limiting disease, it would likely suppress or alter the profile of cytokines 
released in response to infection.  A comparison of cytokine RT-PCR in influenza infected vs. 
control tissues would provide insight into cytokines that may be suppressed or enhanced in 
response to infection.  
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This project has tested the efficiency of a novel antiviral protein, HB36.6, to protect 
against influenza A.  We anticipated that HB36.6 would be effective at reducing viral loads and 
limiting disease compared to untreated controls, and believed HB36.6 would be more effective 
than Tamiflu in the ferret model.  This new class of antivirals has the potential to be further 
evaluated in humans, and once further expanded, can be used as a prophylactic or therapeutic 
treatment for many types of influenza.  
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3.0  MATERIALS AND METHODS 
3.1 BIOSAFETY 
All experiments using live influenza A H1N1 virus were performed in a biosafety level 2 
(BSL-2) laboratory in the Center for Vaccine Research at the University of Pittsburgh.  
Protective gowns and latex gloves were worn when working with live virus under a class II 
biosafety cabinet (BSCII).  The cabinet was sterilized using Vesphene IIse (STERIS 
Corporation, cat. #6461-08) diluted 1:128 with water, and 70% ethanol as disinfectants.  All 
personnel were trained in sterile technique as well as working with infectious virus prior to being 
able to work independently with influenza virus.  The laboratory was inspected and monitored at 
least annually by the Department of Environmental Health & Safety. 
3.2 VIRUS PROPAGATION 
A stock of 2009 H1N1 influenza virus A/California/07/2009 (2.6 x 108 CEID50/ml 
obtained from BEI Resources, cat. # NR-13663) was used to infect white leghorn fertile specific 
pathogen-free chicken eggs obtained from Charles River (North Franklin, CT) using the 
procedure described in Appendix A.  A high virus titer of 2.6 x 107 TCID50/ml was confirmed 
using TCID50 to measure cytopathic effect in MDCK cells. 
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3.3 AEROSOL INOCULATION 
Aerosol exposure containing harvested influenza H1N1 virus was performed using a 3-jet 
Collison nebulizer (BGI, Inc. Waltham, MA).  The nebulizer is located inside a class III 
biological safety cabinet (Baker Co., Sanford, ME) maintained under negative pressure, and is 
controlled through the AeroMP bioaerosol exposure system (Biaera Technologies, Hagerstown, 
MD) [27].  It creates a uniform particle aerosol between 1-2 µm in size, which deposits in the 
deep lung.  The ferrets were placed in wire-mesh cages, one ferret per cage, and transported into 
the regional biocontainment laboratory (RBL) to the aerosol suite for exposure inside a whole-
body aerosol inhalation chamber (Biaera Technologies).  All ferrets were exposed to the aerosol 
for 20-30 minutes (20 min for study #2 and 30 min for studies #3 and #4) followed by a 5-minute 
air wash, after which they were returned to the animal holding facility.  
Aerosol concentration of the virus was determined through constant sampling of the 
chamber using an all-glass impinger (AGI; Ace Glass, Vineland, NJ) containing 10 ml viral 
growth media.  Presented dose was calculated using Guyton’s formula (Vm = 2.10 ± Wb0.75, 
where Wb is body weight) for respiratory minute volume (Vm) [28], and multiplying the total 
volume (Vt) of experimental atmosphere inhaled (Vt = Vm x length of exposure) by the aerosol 
concentration (Ce) (presented dose = Ce x Vt) [29]. 
For Fuller Ferret Study #2 exposure took place in 3 runs of 4 ferrets for 20 minutes.  The 
nebulizer concentration was 1.65 x 105 TCID50 with a spray factor (SF) of 7.56 x 10-7 (runs #1 
and #3) and 1.11 x 10-6 TCID50 (run #2).  The average presented dose was estimated to be 879 
TCID50 of pH1N1.  For study #3 exposure took place in 3 runs of 3 ferrets for 30 minutes.  The 
nebulizer concentration was 1.47 x 105 TCID50 with a SF of 1.2 x 10-6 (runs #1 and #3) and 1.6 x 
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10-6 TCID50 (run #2).  The average presented dose was estimated to be 1,711 TCID50 of pH1N1.  
For study #4, exposure took place in 4 runs of 3, 3, 4, and 3 ferrets (total 13 ferrets) for 30 
minutes.  The nebulizer concentration was 4.22 x 106 TCID50 with a SF of 5.56 x 10-8 (run #1), 
8.98 x 10-8 (runs #2 and #3), and 2.36 x 10-7 TCID50 (run #4). The average presented dose was 
estimated to be 4,818 TCID50 of pH1N1.  Individual inhaled dose per ferret for all studies can be 
seen in Appendix B. 
3.4 FERRET STUDIES 
For each study, H1N1 sero-negative ferrets were received through the Division of 
Laboratory Animal Resources (DLAR) from Triple F Farms (Sayre, PA).  Ferrets were housed 
and necropsied in the animal holding and procedure room of a BSL-2 facility, and were under 
the watchful care of DLAR technicians for the duration of the study.  The University of 
Pittsburgh abides by all federal regulations governing the use of animals in research in the U.S. 
and is an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
accredited institution.  All procedures were approved by the University of Pittsburgh’s 
Institutional Animal Care and Use Committee (IACUC).  Ferrets were subcutaneously 
microchipped using IPTT-300 implantable electronic ID transponders (BioMedic Data Systems, 
Inc., Seaford, DE) after arrival and allowed to acclimate before aerosol infection with 
A/California/07/09 pandemic H1N1 (pH1N1) influenza virus. 
Each ferret weight, temperature, and clinical score was recorded daily starting before 
infection at day 0 through necropsy.  Ferrets were monitored using clinical assessment sheets 
developed by Dr. Deborah Fuller’s laboratory (University of Washington) in collaboration with 
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the Cole lab.  This assessment encompasses the categories of appearance, movement, pulmonary 
function, and consumption/elimination (shown in Appendix A).  Clinical assessments were 
performed and recorded by both DLAR technicians and Cole lab members.  In the event that 
ferrets displayed severe signs of disease, the DLAR veterinarian was consulted.  The study 
design called for any ferret that lost ≥30% of their total body weight or that reached a clinical 
score of 10 in two or more of the clinical scoring areas and lost ≥20% of their body weight to be 
humanely sacrificed. 
Ferret samples were collected for evaluation of viral, immunologic and pathologic 
evaluation of influenza infection.  For all ferret samples, ferrets were sedated with 4% isoflurane 
by canine masking.  Sedation was confirmed by toe pinch and slow steady breathing.  Once 
sedated, nasal washes were collected daily for all studies; blood was collected daily for study #2, 
and on day 0 and necropsy for studies #3 and #4.  Tissue and BAL were harvested at necropsy 
and were either flash frozen on dry ice until storage at -80°C or stored in 10% formalin (Fisher 
Scientific, cat. #SF984).  The day following necropsy, the tissues in formalin were moved to 
clean tubes containing fresh formalin for eventual removal from the lab for pathology. Ferrets 
were held until they displayed signs of awakening from anesthesia, then were returned to their 
cages.  Ferrets were monitored until they were fully awake and moving freely about their cages. 
3.4.1 Study #2 
Eleven ferrets, ages 16 to 18 weeks old and weighing between 0.70 and 0.86 kg, were 
received for this study.  Three ferrets were given 10mg/kg of HB36.6 2 hours prior to pH1N1 
challenge (medium-dose), four ferrets were given 2.5mg/kg of HB36.6 2 hours prior to pH1N1 
infection (low dose), and four ferrets were used as untreated controls.  All eleven ferrets were 
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aerosol challenged with pandemic H1N1, 2.6 x 107 A/California/07/09 TCID50, and received an 
average inhaled dose of 879 TCID50.  The ferrets were monitored and sampled (nasal wash and 
blood) for 3 days following influenza infection, after which they were humanely sacrificed and 
necropsied on day 3 post infection.  
 
Figure 4. Study #2: Evaluate HB36.6 prophylactically in the ferret model using different doses of treatment 
compared to untreated control ferrets. 
All ferrets were aerosol challenged with 2.6 x 107 TCID50/ml of A/California/7/2009(H1N1) influenza virus.  Two 
hours prior to infection, three ferrets were treated with 10mg/kg HB36.6 and four ferrets were treated with 2.5mg/kg 
HB36.6.  Blood and nasal wash samples were collected daily, and clinical scoring was completed daily. 
3.4.2 Study #3 
Eleven ferrets, 16 to 18 weeks old and weighing between 0.67 and 0.81 kg, were received 
for this study.  All ferrets were allowed to acclimate for 72hr after arrival before being 
microchipped.  Two of the eleven ferrets were given 15mg/kg of HB36.6 2 hours before 
anticipated influenza challenge, but due to the limited volume of HB36.6 we were allowed to 
administer, we were unable to achieve the desired 20 mg/kg dose (IACUC protocol limited us to 
administration of ≤1cc per ferret at any one treatment period) these ferrets were pulled from 
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study #3 and not challenged.  Instead they were allowed to rest and the antiviral (15mg/kg 
HB36.6) was given time to decay before use in study #4.  The remaining 9 ferrets were used for 
study #3.  Four ferrets were given 20mg/kg of HB36.6 binder 24 hours prior to pH1N1 
challenge, two ferrets were given 20mg/kg of binder two hours prior to pH1N1 infection, and 
one ferret was given 10mg/kg of binder two hours pre-challenge with pH1N1 virus.  Two ferrets 
were used as untreated controls.  All nine ferrets were aerosol challenged with 2.6 x 107 TCID50 
A/California/07/09 pandemic H1N1 and received an average inhaled dose of 1,711 TCID50.  The 
ferrets were monitored and sampled (daily nasal washes) for 6 days following influenza 
infection, after which they were humanely sacrificed and necropsied on day 6 post infection. 
 
Figure 5. Study #3: Evaluate treatment with HB36.6 received at different prophylactic time points in the 
ferret model compared to untreated control ferrets.   
All ferrets were aerosol challenged with 2.6 x 107 TCID50/ml of A/California/7/2009 (H1N1) influenza virus.  All 
treated ferrets received a single dose of 20mg/kg HB36.6; two ferrets were treated two hours before infection, and 
four ferrets were treated 24 hours before infection.  Nasal wash samples were collected daily, and clinical scoring 
was completed daily.  Blood samples were taken preinfection on day 0 and before necropsy on day 6. 
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3.4.3 Study #4 
Eleven ferrets, 16 to 18 weeks old and weighing between 0.62 and 0.83 kg, were received 
for study #4.  Two ferrets were given 20mg/kg of HB36.6 binder two hours prior to challenge 
with pH1N1, 4 ferrets were given 20mg/kg of binder once daily from days 1 to 5, and 4 ferrets 
were given 5mg/kg oseltamivir (Tamiflu) twice daily (morning and evening dose; dosing based 
on weight as directed).  One ferret was used as an untreated control.  All eleven ferrets were 
aerosol challenged with 2.6 x 107 TCID50 A/California/07/09 pandemic H1N1 and received an 
average inhaled dose of 4,818 TCID50.  The ferrets were monitored and sampled (daily nasal 
washes) for 6 days following influenza infection, after which they were humanely sacrificed and 
necropsied on day 6 or 7 post infection. 
 
Figure 6. Study #4: Compare the efficacy of therapeutic HB36.6 treatment in ferrets to the currently used 
antiviral, Tamiflu.   
All ferrets were aerosol challenged with 2.6 x 107 TCID50/ml of A/California/7/2009 (H1N1) influenza virus.  All 
HB36.6-treated ferrets received 20mg/kg HB36.6; two ferrets were treated two hours before infection, and four 
ferrets were treated daily on days 1-5 post infection.  Four ferrets were treated with 5mg/kg Tamiflu twice daily on 
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days 1-5 post infection.  Nasal wash samples were collected daily, and clinical scoring was completed daily.  Blood 
samples were taken preinfection on day 0 and before necropsy on day 6 or 7. 
3.1 BLOOD COLLECTION 
Ferrets were isoflurane sedated by canine mask and blood was collected from the cranial 
vena cava using a 1cc syringe with a 25g safety needle.  Blood was transferred to a 3cc heparin 
blood tube (Becton Dickinson), inverted several times and stored at room temperature until all 
samples were collected.  Blood was taken to the lab, centrifuged at 1500rpm for 10 min to 
separate plasma from serum, and samples were stored at -80°C. 
3.2 NASAL WASH COLLECTION 
Nasal washes were performed with 1 ml (studies #2 and #3) or 2 ml (study #4) of sterile 
saline administered with an endotracheal tube on the end of a 3cc syringe.  Saline was slowly 
dripped into the nares of isoflurane-sedated ferrets and then collected by gravity into sterile petri 
dishes.  Ferret noses were additionally swabbed internally with a 6-inch sterile polyester-tipped 
applicator (Fisher Scientific, cat. #23-400-122).  Samples were combined (polyester-tipped 
applicator in saline) and stored at -80°C.  Real-time PCR was used to analyze samples after RNA 
extraction.  To extract RNA from dry samples, PBS was used to wash the polyester-tipped 
applicator. 
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3.3 SAMPLES COLLECTED AT NECROPSY 
At the end of each study, ferrets were humanely sacrificed.  Ferrets were heavily sedated 
with 4% isoflurane, confirmed by toe pinch and slow, steady breathing.  Nasal washes and final 
bleeds were performed as described above.  Ferrets were then humanely sacrificed by injection 
of Beuthanasia at 5 mg/kg directly into the heart.  Following injection, the absence of breathing 
and heart rate were confirmed before performing the necropsy.   
For necropsy, the animals were moved to a sterile work space on the bench or inside a 
BSC.  Bronchoalveolar lavage (BAL) was collected from all ferrets at necropsy using 10 ml 
sterile PBS administered into the lobes of the lungs via a feeding tube connected to a 10cc 
syringe.  Once administered, the liquid was gently withdrawn, with approximately 50-60% 
recovery of liquid instilled.  Following the BAL, the ferret was opened, and a gross pathological 
evaluation of organs was performed.  Samples of most organs were obtained and either flash-
frozen on dry ice/ethanol (nasal wash, BAL, trachea, 4 different lung lobes, nasal turbinate) or 
preserved in 10% paraformaldehyde (trachea, 2 lung lobes, nasal turbinate).    If indicated by 
disease course, a craniotomy was performed, and brain sections and spinal cord were also 
collected. 
3.4 RNA EXTRACTION  
Tissue sample RNA was isolated using a Qiagen RNeasy Mini Kit (Germantown, MD, 
cat. #74104) and RNase-free DNase Set (Germantown, MD, cat. #79254) for on-column DNase 
digestion and homogenates were used for PCR analysis.  From each tissue, approximately 
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400mg was homogenized in DMEM with 2% FBS, and RNA was extracted using TRI Reagent 
Solution (Ambion, Thermo Fisher Scientific, cat. #AM9738).  Liquid sample RNA was extracted 
using an Invitrogen PureLink Viral RNA/DNA Mini Kit (Carlsbad, CA, cat. #12280-050).  
After extraction, one-step quantitative real-time reverse-transcription PCR was performed using 
the SuperScript III Platinum One-Step qRT-PCR Kit with ROX (Invitrogen, cat. #11745-
100) following the protocol in Appendix A.  All samples were detected using reagents provided 
in the Swine Influenza A (H1N1) Real-Time RT-PCR Assay kit (BEI Resources, cat. #NR-
15577).  All samples from study #2 were detected using the Swine Influenza H1 (swH1) 
primers/probe set based on the detection of the H1N1 HA gene (nucleotide sequence listed in 
Appendix A).  Nasal wash RNA from days 3 and 6  (studies #3 and #4) were also detected using 
the swH1 primers/probe set.  Nasal Swab (Days 0, 1, 2, 4, and 5; study #3) and lung 4/6 RNA 
(study #3 and #4) were detected using the Universal Influenza A (InfA) primer/probe set based 
on the detection of the H1N1 matrix (M) gene [30].   
PCR of standards accompanied the samples; the standards were ten-fold dilutions (10-1 
through 10-6) of the A/California/07/2009 (BEI Resources, cat. #NR-13663) pandemic H1N1 
virus (original titer: 2.8 x 108 CEID50/ml) made by Dr. Amy Hartman.  A second set of standards 
had to be made when Dr. Hartman’s stocks ran out.  This new standard curve consisted of 10-
fold dilutions (10-1 through 10-6) of A/California/04/09 (gift provided by Dr. Stacy Schultz-
Cherry, St. Jude Children’s Research Hospital) pandemic H1N1 virus (original titer: 108.25 
TCID50/ml).  Known viral titers were used to calculate quantities for the standard curve and 
quantities were verified by PCR.  See Appendix A for making a standard curve and quantities of 
the standard curves used.  Standard curve cycle threshold (Ct) values began at cycle ~13 for both 
swH1 and InfA primer/probe sets and each dilution was ~4 cycle thresholds above the next. 
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3.5 QRT-PCR FOR VIRUS TITERS 
To analyze samples, real-time RT-PCR was performed using a 7900HT Fast Real-Time 
PCR System (Applied Biosystems, Carlsbad, CA) using the reagents and methods in Appendix 
A.  PCR was designed to run for 40 cycles using the parameters listed in Appendix A and AH 
H1N1 (for Universal Influenza A primer/probe set) or SW Inf H1 (for Swine Influenza H1 
primer/probe set) as the detector.  When the standards and controls met the expected results, the 
unknown samples were considered positive for pH1N1 if the reaction growth curve crossed the 
threshold line within 37 cycles. 
3.6 CYTOKINE DETECTION 
3.6.1 ELISA 
An enzyme-linked immunosorbent assay (ELISA) was used in an attempt to detect 
interferon (IFN)-γ in ferret serum and blood samples from study #2 following an adapted 
protocol developed from [11] (shown in Appendix A).  Antibodies used include Monoclonal 
Anti-Ferret Interferon Gamma, Clones 4A4B7 and 1H1H12 (BEI Resources, cat. #NR-4492 and 
#NR-4493), and peroxidase conjugated Goat Anti-Ferret IgG IgA IgM Antibody (Rockland 
Immunochemicals Inc., Limerick, PA).  Optical density was determined using a PowerWave XS 
(BioTek) and SpectraMax L plate reader at 450nm. 
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3.6.2 RNA Extraction and cDNA Synthesis 
RNA isolation was performed on serum, blood, peripheral blood mononuclear cell 
(PBMC) and nasal wash samples using the RNeasy Mini Kit (Qiagen, cat. #774104) with on-
column DNase Digestion (cat. #79254), PureLink Viral RNA/DNA Kit (Invitrogen, cat. #12280-
050), or QIAamp Viral RNA Mini Kit (Qiagen, cat. #52904).  Then first strand cDNA 
synthesis was performed with 5µg RNA using the Maxima First Strand cDNA Synthesis Kit 
(Thermo Scientific, cat. #K1642).  Primer sequences for ferret IFN-γ, tumor necrosis factor 
(TNF)-α, interleukin (IL)-10, and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(Integrated DNA Technologies, Coralville, IA) can be found in Appendix A. 
3.6.3 Cytokine PCR 
Two-step quantitative real-time RT-PCR was performed using Maxima SYBR 
Green/ROX qPCR Master Mix (2X) (Thermo Scientific, cat. # K0221) with ≤500 ng Template 
DNA (not to exceed 10% of the total PCR volume).  Analysis was done using a 7900HT Fast 
Real-Time PCR System (Applied Biosystems, Carlsbad, CA) set to the parameters listed in 
Appendix A.  Upon successful detection of cytokines using PCR, expression levels should be 
normalized to Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) and calculated as fold 
change compared to day 0 ferrets based on the ∆∆Ct method.  The change in threshold cycle 
(∆Ct) is calculated by subtracting the gene of interest at each time point from the GAPDH Ct 
value.  Then fold change is calculated by subtracting the day 0 ∆Ct values from the subsequent 
days ∆Ct values.  The formula: fold change = 2−∆∆Ct is then used to obtain absolute values [31]. 
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4.0  RESULTS 
The goal of these studies was to evaluate a novel antiviral, HB36.6, for its ability to 
inhibit infection of aerosolized influenza in the ferret model.  To accomplish this, three animal 
studies were performed which evaluated dose and timing of treatment pre-infection as well as a 
therapeutic treatment regimen, including the standard of care Tamiflu, after aerosol exposure to 
pH1N1.  Fuller Ferret Study #2 was a three-day low-dose (2.5mg/kg or 10mg/kg) prophylactic 
study with antiviral protein HB36.6.  Study #3 was a six-day high-dose prophylactic study with 
20mg/kg HB36.6.  Study #4 was a six-day high-dose (20mg/kg) therapeutic study compared to 
the currently marketed antiviral, Tamiflu (5mg/kg as recommended).  All ferrets were challenged 
with A/California/07/09 pandemic H1N1 and assessed daily using a detailed clinical scoring 
system.  Blood, nasal wash, and tissue samples were harvested for virologic, immunologic and 
pathologic analyses to compare treated and untreated ferrets following aerosolized influenza 
infection. 
Ferrets were prescreened for influenza negative status prior to selection for studies.  For 
these analyses, hemagglutinin inhibition (HAI) assays were performed on the ferret sera to 
demonstrate lack of antiviral H1N1 antibodies prior to delivery to the University of Pittsburgh.  
HAI assays for study #2 were performed by Dr. Amy Hartman using ferret serum received 1-2 
weeks before beginning the study; HAI assays for studies #3 and #4 were performed by the Cole 
lab.   
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Based on confounding results obtained with study #4, (mainly that two of the three 
untreated controls were minimally infected post challenge), HAI assays were also performed on 
serum collected at day 0 and necropsy to determine whether these ferrets had antibodies for 
influenza, demonstrating that they had been exposed/infected with influenza at the University of 
Pittsburgh prior to initiation of study #4.  Study #4 control ferrets F15-010 and F15-011 had 
positive antibody responses in the HAI assay, explaining the low level of virus infection post 
challenge. 
4.1 AIM 1: TO DETERMINE WHETHER TREATMENT WITH HB36.6 
RESULTS IN REDUCED CLINICAL SIGNS OF DISEASE COMPARED TO 
UNTREATED CONTROLS FOLLOWING AEROSOLIZED INFLUENZA 
INFECTION IN THE FERRET MODEL   
 Observations for clinical signs of disease are an indicator of disease severity.  Ferrets 
were assessed each morning for clinical signs of disease that included measurement of weights, 
temperatures, and observations that were recorded using a detailed clinical scoring sheet (shown 
in Appendix A).  Temperature (°C) is shown for each group throughout the duration of the study 
in the form of a line graph.  Weight information is displayed as percentage change compared to 
day 0 measurements in the form of a line graph.  Clinical score data is displayed as a dot plot.  A 
clinical score of 0 indicates no symptoms or normal behavior, and increased numbers correlate 
with increased signs of disease.  All scores were adjusted to reflect additional written notes 
recorded by either the investigator or DLAR team that were not part of any category on the 
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clinical assessment sheet.  Formal statistics were only completed for study #2, where the sample 
size was 3 or 4 for each experimental group. 
4.1.1 Study #2 
Study #2 evaluated low dose HB36.6 treatment in ferrets aerosolized with influenza.  
Elevations in temperatures were observed in all experimental groups, peaking at day 2 post 
infection (PI) and either returning to preinfection baseline or plateauing on day 3 PI (Figure 7A).  
While treated ferrets (2.5mg/kg and 10mg/kg) displayed greater weight loss over time compared 
to untreated control ferrets, these differences did not achieve significance (Figure 7B).  For 
example, control ferrets experienced approximately 2% weight loss, while treated ferrets 
averaged approximately 5% weight loss.  The untreated control group displayed significantly 
more severe clinical signs of disease (reduced food/water intake, increased nasal discharge, 
lethargy) by days 2 and 3 than the treated ferrets (Figure 7C).   
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Figure 7. Clinical signs of disease in ferrets treated with low doses of HB36.6 and untreated control ferrets 
after aerosol exposure to A/California/07/09 (H1N1).  
Study #2 consisted of four untreated control ferrets (black circles), four ferrets treated with 2.5mg/kg HB36.6 two 
hours before infection with pH1N1 (purple squares), and three ferrets treated with 10mg/kg HB36.6 two hours 
before infection (teal triangles).  Ferrets were challenged with 2.6 x 107 TCID50 A/California/07/09.  (A) 
Temperature (°C) of treated and untreated control ferrets over the course of infection.  (B) Percentage of weight 
change of treated and untreated control ferrets over the course of infection. (C) Individual ferret clinical scores for 
treated and untreated control ferrets over the course of infection. Graphs A and B are shown with mean and SD at 
each time point.  Graph C is shown with mean at each time point.  Statistical analysis was done using a two-way 
ANOVA for multiple comparisons where α = 0.05. 
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4.1.2 Study #3 
Study #3 evaluated high dose (20mg/kg) HB36.6 treatment prior to influenza infection.  
For study #3, no notable changes in temperature were observed between treated and untreated 
groups (Figure 8A).  All groups experienced weight loss.  The untreated control group and 
ferrets treated with 20mg/kg at 24 hours before infection (−24hr) experienced the highest 
percentage in weight loss, demonstrating maximum average weight loss (15-20%) on day 3 PI 
(Figure 8B). This was in marked contrast to ferrets treated with 20mg/kg two hours before 
infection (−2hr), with only ~9% weight loss on day 3 and remaining steady up until ~11% weight 
loss on day 6 PI.  On days 4 through 6 PI, untreated control ferrets displayed more severe clinical 
signs of disease than the treated groups, with -24h ferrets (treated with 20mg/kg HB36.6 at 
−24hr) displaying the fewest symptoms overall (Figure 8C).  It was not possible to evaluate 
statistical significance due to the small sample size of untreated control ferrets and ferrets treated 
with 20mg/kg HB36.6 at −2hr (N=2). 
 
 
 
 41 
 
Figure 8. Clinical signs of disease in ferrets treated with a high dose of HB36.6 and untreated control ferrets 
after aerosol exposure to A/California/07/09.   
Study #3 consisted of two untreated control ferrets (black circles), two ferrets treated with 20mg/kg HB36.6 two 
hours before infection with H1N1 (blue squares), and four ferrets treated with 20mg/kg HB36.6 24 hours before 
infection (red triangles).  Ferrets were challenged with 2.6 x 107 TCID50 A/California/07/09.  (A) Temperature (°C) 
of treated and untreated control ferrets over the course of infection.  (B) Percentage of weight change of treated and 
untreated control ferrets over the course of infection.  (C) Clinical scores of treated and untreated control ferrets over 
the course of infection.  Graphs A and B are shown with mean and SD at each time point.  Graph C is shown with 
mean at each time point. 
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4.1.3 Study #4 
 Study #4 was designed to evaluate the therapeutic potential of HB36.6 in comparison to 
the standard of care, Tamiflu.  Temperatures for all groups remained close to baseline (day 0) 
throughout each day of the study, with no clear trend as observed in studies #2 and #3. (Figure 
9A).  Ferrets in all 4 groups demonstrated weight loss for the duration of the study, with the 
HB36.6 treated ferrets having the most weight loss (Figure 9B).  Percentage of weight lost is 
similar for all ferrets until day 4 PI.  Percentage weight loss in ferrets treated with Tamiflu 
plateaued on day 4 (at approximately −10%) and remains the same until necropsy.  Untreated 
control ferrets increase in weight slightly from day 4 to day 5, then also plateau at about −12%.  
Ferrets treated with 20mg/kg on D1-5 and 20mg/kg at −2hr experience similar consistent 
percentage weight change throughout the study, ending at approximately −20% on day 6.  The 
20mg/kg HB36.6 at D1-5 treated group displayed the most severe clinical signs of disease 
throughout the duration of the study (Figure 9C).  Statistics could not be determined due to a 
sample size of 1 (N=1) for the untreated control comparison. 
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Figure 9. Clinical signs of disease in ferrets treated with a high dose of HB36.6 or Tamiflu, and untreated 
control ferrets after aerosol exposure to A/California/07/09.   
Study #4 consisted of one untreated control ferret (black circles), two ferrets treated prophylactically with 20mg/kg 
HB36.6 two hours before infection with H1N1 (blue squares), four ferrets treated therapeutically with 20mg/kg on 
days 1-5 PI of the study (green triangle), and four ferrets treated therapeutically with Tamiflu (5mg/kg, twice daily 
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on days 1-5) (pink inverted triangles).  Ferrets were challenged with 2.6 x 107 TCID50 A/California/07/09.  (A) 
Temperature (°C) of treated and untreated control ferrets over the course of infection.  (B) Percentage of weight 
change of treated and untreated control ferrets over the course of infection.  (C) Clinical scores of treated and 
untreated control ferrets over the course of infection. Graphs A and B are shown with mean and SD at each time 
point.  Graph C is shown with mean at each time point.  Statistics cannot be used to analyze these data due to a 
sample size of N=1 for the control. 
4.1.4 Summary of Aim 1 
Studies #2 and #3 showed that ferrets treated with HB36.6 displayed fewer clinical signs 
of disease compared to untreated control ferrets, and for study #2 these differences were 
significant.  The data obtained in study #4 was complicated by several experimental problems, 
the most notable being that 2 of the 3 control animals did not become infected post influenza 
challenge.  This was determined to be due to prior exposure to influenza from the 
facility/workers while in holding between studies #3 and #4 at the University of Pittsburgh.  In 
addition, study #4 used a different stock of challenge virus resulting in a much higher delivered 
dose, and there were unexpected results with the Tamiflu treated controls.  Finally, the high dose 
(20mg/kg) HB36.6-treated animals demonstrated some irritation to the drug alone, resulting in 
diarrhea and reduced appetite, complicating the results post infection.  Altogether, it will be 
necessary to repeat study #4 to obtain reliable data that can be compared to studies #2 and #3.   
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4.2 AIM 2: TO DETERMINE WHETHER TREATMENT WITH HB36.6 
REDUCES VIRAL TITERS IN NASAL WASH AND LUNG TISSUE SAMPLES 
COMPARED TO UNTREATED CONTROLS FOLLOWING AEROSOLIZED 
INFLUENZA INFECTION IN THE FERRET MODEL 
The goal of Aim 2 was to further evaluate the virologic and immunological properties of 
the samples obtained in studies #2, #3 and #4.  Measurement of viral loads by semi-quantitative 
reverse transcriptase RT-PCR is presumed to be reflective of infectious virus particles.  Thus, a 
higher viral load is generally associated with more severe disease in the ferret model.  To 
quantitate the virus in ferret samples post infection, nasal wash samples were collected daily and 
lung tissue samples were harvested at necropsy for evaluation.   RNA was extracted and semi-
quantitative reverse transcriptase RT-PCR was performed to quantitate the viral copies.  Data is 
displayed using dot plots with mean shown.  Formal statistics were only completed for study #2, 
where groups consisted of 3 or 4 ferrets. 
4.2.1 Study #2 
Study #2 was designed to evaluate the ability of HB36.6 to reduce virus when given prior 
to infection at a low dose.  RT-PCR on these study #2 samples was performed by Dr. Amy 
Hartman.  Viral titers were highest in nasal wash samples for all groups on day 2 PI (Figure 
10A).  Untreated controls had the highest viral copy levels on days 1 and 2 PI; viral copies were 
reduced in the HB36.6 treated ferrets in a dose-dependent manner (10 mg/kg group had a mean 
viral load of 1.14 x 105 compared to the 2.5 mg/kg group having a mean viral load of 4.00 x 105 
on day 2 PI) (Figure 10B).  Similar results were observed in lung tissue, where the untreated 
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controls demonstrated the highest average viral titers (2.65 x 105), followed by the 10 mg/kg 
treated group (1.97 x 105), and the 2.5 mg/kg treated group having the lowest average amount of 
virus (3.84 x 103).  Taken together these data suggest that HB36.6 is able to reduce the viral load 
when administered pre-infection at low doses. 
 
Figure 10. Quantification of viral loads in nasal wash and lung samples in ferrets treated with low doses of 
HB36.6 and untreated control ferrets after aerosol exposure to influenza virus A/California/07/09.   
Study #2 consisted of four untreated control ferrets (black circles), four ferrets treated with 2.5mg/kg HB36.6 two 
hours before infection with pH1N1 (purple squares), and three ferrets treated with 10mg/kg HB36.6 two hours 
before infection (teal triangles).  Ferrets were challenged with 2.6 x 107 TCID50 A/California/07/09. (A) Nasal wash 
viral copies in ferrets groups after aerosolized infection with pH1N1, displayed as a dot plot to show individual 
ferret data.  (B) Ferret viral copies detected in lung 4/6 on day 3 PI.  Graphs are shown with mean at each time point.  
Statistical analysis on nasal wash data was performed using a two-way ANOVA for multiple comparisons. 
4.2.2 Study #3 
Study #3 evaluated high dose (20mg/kg) HB36.6 at two time points pre-infection to 
determine how early prior to infection the antiviral could be administered and still have an effect 
on blunting influenza infection and disease progression in ferrets.  Evaluation of nasal wash 
samples from these ferrets demonstrated that virus peaked on day 3 PI (Figure 11A) with a mean 
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viral load ranging from 2.58 to 6.82 x 104 in untreated controls and HB36.6 treated groups, 
respectively.  Differences in viral loads in lung tissue from treated animals compared to 
untreated controls were not as substantial as observed in study #2 and we actually observed less 
virus in the controls compared to the treated animals (Figure 11B).  It should be noted that on 
day 3 PI most animals received fluids due to their level of dehydration.  On day 5 PI we observed 
an increase in virus and a decrease in clinical scores, presumably due to the increase in level of 
hydration of the animals.  However, most animals regressed and by day 6 their scores and viral 
loads returned close to their day 3 or 4 levels.  There were two differences in study #3 compared 
to study #2 that are worth noting.  First, study #3 was carried out to 6 days post infection while 
study #2 only lasted 3 days PI.  This longer duration of study made comparison of the viral loads 
in lung tissue impossible, and given that all treated animals received antiviral treatment prior to 
infection, it is unlikely that the antiviral would be able to continue to inhibit virus for 6 days.  
Thus we are likely seeing an increase in virus replication after 2-3 days PI of virus that was not 
controlled by HB36.6 treatment.  Second, the HB36.6 dose was higher in study #3 and some 
irritability was observed in the ferrets following administration prior to influenza infection.  
Regardless, study #3 did not demonstrate any major changes in viral loads in ferrets treated with 
HB36.6 administered within 24hr prior to influenza infection compared to untreated controls. 
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Figure 11. Quantification of viral loads in nasal wash and lung samples in ferrets treated with a high dose of 
HB36.6 and untreated control ferrets after aerosol exposure to influenza virus A/California/07/09.  
Study #3 consisted of two untreated control ferrets (black circles), two ferrets treated with 20mg/kg HB36.6 two 
hours before infection with H1N1 (blue squares), and four ferrets treated with 20mg/kg HB36.6 24 hours before 
infection (red triangles).  Ferrets were challenged with 2.6 x 107 TCID50 A/California/07/09.  Viral loads were 
measured by semi-quantitative reverse-transcriptase RT-PCR following aerosolized pH1N1 infection in (A) nasal 
wash, and (B) lung tissue at necropsy.  All data is represented with the mean at each time point.  Statistics could not 
be analyzed with these data due to a sample size of N=2 in some groups.   
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4.2.3 Study #4 
Study #4 set out to further evaluate HB36.6 therapeutically and compare it to the standard 
of care, Tamiflu.  For this study, ferrets were treated with a high dose (20mg/kg) of HB36.6 
before or after aerosolized influenza infection and compared to untreated controls and Tamiflu 
treated ferrets.  Viral loads were again measured in longitudinal nasal wash samples and lung 
tissue from necropsy.  Due to experimental issues, 2 of 3 untreated control ferrets failed to 
become infected leaving the study with inadequate controls.  Further, the high dose of HB36.6 
resulted in more evident irritability in the ferrets with observed loss of appetite and diarrhea 
following each dose.  As a result of these issues, viral loads in nasal washes were only slightly 
different among the treatment groups (Figure 12A).  Interestingly, while differences were not as 
striking as earlier experiments, there was an overall trend toward decreasing viral loads in nasal 
wash samples early after infection (day 3) in HB36.6-treated ferrets.  These data show that 
treatment prior to infection was just as effective as daily treatment on days 1-5 after infection, 
though these differences were not substantial.  Further, the lung samples at necropsy did not 
mirror the nasal wash results (Figure 12B).  It will be necessary to repeat study #4 to obtain 
reliable data.  
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Figure 12. Quantification of viral loads in nasal wash and lung samples in ferrets treated with a high dose of 
HB36.6 or the recommended dose of Tamiflu, and untreated control ferrets after aerosol exposure to 
influenza virus A/California/07/09.   
Study #4 consisted of one untreated control ferret (black circles), two ferrets treated prophylactically with 20mg/kg 
HB36.6 two hours before infection (blue squares), four ferrets treated therapeutically with 20mg/kg on days 1-5 PI 
(green triangles), and four ferrets treated therapeutically with Tamiflu (5mg/kg, twice daily on days 1-5) (pink 
inverted triangles).  All Ferrets were challenged with 2.6 x 107 TCID50 of aerosolized influenza A/California/07/09, 
and viral loads were measured in (A) nasal washes on day 3 and 6 PI, and (B) lung tissue at necropsy.  Data is 
represented with mean at each time point.  Statistics could not be analyzed in all groups due to low sample numbers 
[control (N=1) and 20mg/kg −2hr groups (N=2)]. 
4.2.4 Summary of Aim 2 
When administered before infection, HB36.6 demonstrates some differences in viral 
loads in nasal wash and lung tissues early on in infection.  These data are complicated from 
issues experienced with higher concentrations of the antiviral HB36.6, especially when the 
binder is administered daily, as the ferrets demonstrated symptoms uncommon with influenza 
infection, including severe diarrhea and loss of appetite.  We believe that HB36.6 may only be 
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helping to block infection for up to day 3 PI, after which the virus is able to replicate more freely 
and differences between the treated and untreated control ferrets starts to narrow.  These longer 
studies need repeated with higher sample sizes to see statistical differences.   
4.3 CYTOKINE DETECTION IN BLOOD AND PLASMA SAMPLES 
Cytokines induced by innate immune responses contribute to more severe clinical 
outcomes in disease.  The Cole lab has previously used semi-quantitative RT-PCR to measure 
specific cytokines in tissue samples, standardized to a housekeeping gene.  However, it is more 
desirable to be able to measure these responses in the periphery (nasal wash and blood) since 
these samples are easier to acquire, and are more realistic samples to study for use in humans.  
Thus, we are currently working to develop a peripheral assay to detect cytokines in ferret 
blood/plasma samples following experimental influenza infection.  We have attempted to 
measure cytokines using an enzyme-linked immunosorbent assay (ELISA) and quantitative real-
time RT-PCR.  For the ELISA, we tried identifying cross-reactive reagents from other species, 
including human, mouse and nonhuman primate.  Other species that have become of interest and 
demonstrated cross-reactivity include the dog and cat (we have not yet tried).  We also identified 
a lab working to generate ferret-specific reagents and contacted them for their assistance.  We 
obtained two protein/antibody combinations donated to the NIH BEI Resources Repository from 
this PI, and after multiple attempts, could not get these reagents to work by ELISA.  We were 
most disappointed to learn that BEI uncovered the fact that the antibodies were not ferret, as 
promised.  We have been able to perform the cytokine RT-PCR and may use this for future 
analyses of the samples.   
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4.3.1 ELISA 
We obtained ferret protein-antibody pairs from Dr. David Kelvin in Canada who 
published on the generation and use of these reagents.  We worked on the development of a new 
ELISA to detect cytokines in the periphery as a comparison to tissue RT-PCR.  Using serum and 
blood (pre-bleed) samples obtained from study #2, we attempted to develop a ferret cytokine 
array using a protocol developed from information provided in [11] to measure IFN-γ, shown in 
Appendix A.  However, we were unable to replicate the Kelvin lab’s results. 
Compared to the blank wells filled with an equivalent volume of blocking solution (1% 
BSA in PBS), there was very little antigen present in the samples in Table 1 using ELISA 
procedure #1 (Appendix A) because the optical density (OD) readings were similarly low.  The 
pre-bleed sample had the highest amount of IFN-γ detected, with 0.120 at a 1:10 dilution, 
followed by the serum sample with 0.096 for the 1:10 dilution.  The serum 1:40 and 1:80 
dilutions must have been switched. 
 
Table 1. IFN-γ Detection in Ferret Serum and Blood Samples Using ELISA Protocol #1 
Sample Task Conc/Dil OD (450nm) 
M-AB 4A4B7 + Control 0.05 0.069 
M-AB 4A4B7 + Control 0.025 0.066 
M-AB 4A4B7 + Control 0.0125 0.071 
M-AB 4A4B7 + Control 0.00625 0.075 
M-AB 1H1H12 + Control 0.05 0.067 
M-AB 1H1H12 + Control 0.025 0.066 
M-AB 1H1H12 + Control 0.0125 0.066 
M-AB 1H1H12 + Control 0.00625 0.068 
Serum Unknown 1:10 0.096 
Serum Unknown 1:20 0.086 
Serum Unknown 1:40 0.069 
Serum Unknown 1:80 0.076 
Pre-bleed Unknown 1:10 0.120 
Pre-bleed Unknown 1:20 0.092 
Blank (Blocker) - Control 0 0.067 
Blank (Blocker) - Control 0 0.064 
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In Table 2, the negative control and positive control had similar OD readings, so these 
results were not considered positive. 
 
Table 2. IFN-γ Detection in Ferret Serum and Blood Samples Using ELISA Protocol #2 
Name Task Conc/Dil OD (450nm) Count Mean Std Dev CV (%) 
IFN-γ Antigen + Control 0.1µg/well 0.071 2 0.069 0.004 5.16 
IFN-γ Antigen + Control 0.1µg/well 0.066     
Serum Unknown 1:10 0.081 2 0.081 0 0 
Serum Unknown 1:10 0.081     
Serum Unknown 1:20 0.081 2 0.082 0.001 1.72 
Serum Unknown 1:20 0.083     
Blank - Control 0 0.067 2 0.068 0.001 1.05 
Blank - Control 0 0.068     
 
4.3.2 Cytokine PCR  
ELISA is the more common method seen in the literature for detection of cytokines in 
serum samples.  However, real-time PCR methods also offer sensitive detection and accurate 
quantification of low levels of cytokine mRNAs, and a number of researchers continue to use 
this method [32, 33].  This method also includes the advantages of the ability to quantify 
multiple targets per well using different fluorochromes, which can reduce costs and time spent 
on experiments [33]. 
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Table 3. Cytokine Detection PCR with Fuller Study #2 Samples 
Primers Sample Detector Task Ct 
GAPDH Plasma #7, D2 SYBR Unknown 12.55983 
GAPDH Plasma #7, Nec SYBR Unknown Undetermined 
GAPDH Plasma #9, D2 SYBR Unknown Undetermined 
GAPDH Plasma #9, Nec SYBR Unknown Undetermined 
GAPDH Lung #7 SYBR + Control Undetermined 
GAPDH Lung #9 SYBR + Control Undetermined 
GAPDH NTC SYBR - Control Undetermined 
GAPDH RT- SYBR - Control Undetermined 
IL-10 Plasma #7, D2 SYBR Unknown Undetermined 
IL-10 Plasma #7, Nec SYBR Unknown Undetermined 
IL-10 Plasma #9, D2 SYBR Unknown Undetermined 
IL-10 Plasma #9, Nec SYBR Unknown 34.69907 
IL-10 Lung #7 SYBR + Control 36.87696 
IL-10 Lung #9 SYBR + Control Undetermined 
IL-10 NTC SYBR - Control Undetermined 
IL-10 RT- SYBR - Control Undetermined 
IFN-γ Plasma #7, D2 SYBR Unknown 26.64936 
IFN-γ Plasma #7, Nec SYBR Unknown Undetermined 
IFN-γ Plasma #9, D2 SYBR Unknown Undetermined 
IFN-γ Plasma #9, Nec SYBR Unknown Undetermined 
IFN-γ Lung #7  SYBR + Control Undetermined 
IFN-γ Lung #9  SYBR + Control Undetermined 
IFN-γ NTC SYBR - Control 4.280223 
IFN-γ RT- SYBR - Control Undetermined 
 
 
In a limited set of experiments to detect cytokine mRNA in our ferret samples, RNA was 
extracted using the RNeasy Mini Kit with on-column DNase Digestion (Qiagen, cat. #774104 
and #79254).  First strand cDNA synthesis was performed using the Maxima First Strand cDNA 
Synthesis Kit (Thermo Scientific, cat. #K1642), and two-step quantitative real-time RT-PCR was 
performed using Maxima SYBR Green/ROX qPCR Master Mix (2X) (Thermo Scientific, cat. # 
K0221).  PCR results were inefficient at best, and the metabolic enzyme GAPDH, used as a 
housekeeping gene in these experiments, was not reliably detecting a signal in all tissues as 
expected.  In addition, the only cytokines detected were IFN-γ in plasma #7, D2 and a very small 
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amount of IL-10 in Plasma #9, Nec and Lung #7 (Table 3).  We attempted RNA extractions 
using the PureLink Viral RNA/DNA Kit (Invitrogen, cat. #12280-050) and QIAamp Viral 
RNA Mini Kit (Qiagen, cat. #52904) with no additional success.  The PCR needs to be 
optimized with known positive samples and then these tissues repeated.   Other housekeeping 
genes in ferret tissues and whole blood samples will also be evaluated as recent literature has 
reported inconsistencies using GAPDH, especially in certain tissues or during disease states [34]. 
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5.0  DISCUSSION 
Evaluation of HB36.6 in the ferret model confirmed studies in mice, demonstrating that 
treatment with this novel antiviral in low to moderate doses (2.5-10 mg/kg) within 24hr prior to 
aerosolized infection resulted in reduction in peak viral load and decreased severity of disease.  
Attempts to increase the dosage resulted in irritation and possible toxicity in the ferrets, 
displayed by their diarrhea and loss of appetite following each dose.  It will be important in 
future studies to determine if there is indeed toxicity from the antiviral through pathology or 
other testing, and to seek alternate formulations that will be less irritating without compromising 
the antiviral potency. 
Studies #2 and #3 afforded important clinical information about the antiviral capabilities 
of HB36.6.  When looking at the data between the two studies, the results demonstrated a similar 
trend of inhibiting viral loads when HB36.6 was administered with 24 hours before infection.   
However, there were also some differences between the studies that warrant further evaluation.  
First, the two studies were designed with different endpoints: study #2 ended on day 3 PI while 
study #3 did not end until day 6 PI.   This is an important distinction since in both studies the 
peak viral load appeared between 2-3 days PI, yet study #3 allowed the animals to progress 
without further antiviral treatment.  This in turn provided time for the virus that was inhibited by 
HB36.6 to begin replicating and, for our analyses, to reflect increases in virus titers.  Thus, future 
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studies should either be shorter to evaluate reduction in peak viral load, or combine prophylactic 
and therapeutic treatments for longer studies. 
In study #2, viral titers did not mimic clinical scores, as viral copies were highest on day 
2 PI, and were beginning to decrease in two groups (untreated controls and 2.5mg/kg treated) by 
day 3 PI, where clinical scores on day 3 were still increasing.  This could indicate that clinical 
signs of disease need time to catch up with a change in viral loads and there is a slight delay in 
feeling sick.  Similar titer amounts were found in the untreated control ferret nasal wash and lung 
samples.  Slightly higher amounts of viral copies were found in the untreated control group lungs 
(~2.65 x 105) compared to their nasal wash (~1.26 x 104) titers.  There was an approximate one 
log10 difference between viral copies in the lung (~3.84 x 103) and nasal wash (~4.86 x 104) 
samples of the 2.5mg/kg treated ferrets on day 3 PI.  Ferrets in study #2 received an average 
inhaled dose of 879 TCID50; this was the lowest average inhaled dose amongst the three studies. 
Contrary to study #2, the untreated control ferrets in study #3 had the greatest weight loss 
over the course of infection, and they were also the group with highest average starting weights.  
One ferret nearly reached the requirements for euthanasia by reaching 29.6% weight loss on day 
3 PI.  This ferret was given 10cc subcutaneous fluids, was watched carefully for a few hours 
after the alarming recorded drop in weight, and had improved when reweighed some time later. 
Similarly to study #2, in study #3 clinical scores were higher for the untreated control group, but 
this did not happen until later into the course of infection (days 4-6) where with lower doses of 
HB36.6, ferrets demonstrated differences in clinical scores by day 2 PI.  Several of the ferrets 
received 10cc subcutaneous fluids at day 3 PI, including both control ferrets [10mg/kg at −2hr, 
N=1; 20mg/kg at −24hr, N=2].  These fluids likely influenced the severity of disease exhibited 
on day 4 PI and help to explain the dip in nasal wash viral loads seen the following day.  
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Reduced viral titers were detected in nasal wash samples on day 6, but not in lungs. Ferrets in 
this study received an average inhaled dose of 1,711 TCID50.  It is likely that a combination of a 
much higher inhaled dose and prolonged study time contributed to the results, potentially 
masking early antiviral benefits (nasal washes only were available for evaluation; no lungs were 
harvested until necropsy). 
 In study #4, ferrets treated with the experimental binder HB36.6 gradually lost the most 
weight by the end of the study, as where the Tamiflu and untreated control groups started to 
plateau in weight at days 4 and 5 PI.  Clinical scores for this study revealed ferrets that received a 
high dose of HB36.6 daily displayed higher clinical signs of disease, and these scores were 
consistent for days 2-6 PI of the study.  Two 20mg/kg daily (D1-5) HB36.6-treated ferrets were 
not sacrificed until day 7 PI, and were beginning to show signs of recovery on this day.  We 
suspect that since the ferrets had not been given binder since day 5, by day 7 they were 
beginning to recover from its toxic affects.  However, our study results are unreliable because we 
only had N=1 for an untreated control comparison, and Tamiflu did not seem to help lessen 
clinical signs of disease, contrary to the literature.  In an article published last year, funded in 
part by the World Health Organization (WHO), researchers concluded that treating influenza-
infected ferrets with oseltamivir (Tamiflu) is associated with improved clinical outcomes, 
including the ferrets remain more active, lose less weight, and experience a smaller rise in body 
temperature throughout the course of infection, despite no significant reduction in viral loads 
[35].  Viral loads on day 6 PI were higher in nasal wash (~3.68-6.23 x 105) than lung samples 
(~1.25 x 101 for controls and ~7.92 x 103 – 2.79 x 104 for treated animals).  Ferrets received an 
average inhaled dose of 4,818 TCID50; this dose was logs higher than those in the previous 
studies. 
 59 
 These three studies with HB36.6 are not directly comparable because different stocks of 
virus were used for each study, the studies took place over varying time points, and the controls 
did not act the same between experiments.  One reason for differences in clinical scores within 
studies could be due to the subjective nature of manually completing clinical scoring sheets.  The 
scoring sheets were primarily completed by Jeneveve Lundy, a DLAR veterinary technician, for 
studies #2 and #4, while study #3 scores were primarily reported by the Cole lab.  WHO 
researchers have reported that using a video tracking method to evaluate the effects of influenza 
infection and treatment on ferret activity is more sensitive at detecting activity changes, and less 
subjective, than manual scoring [35].  The doses of virus used to infect ferrets were very high to 
ensure all ferrets became infected.  Fuller ferret study #1, which is not discussed as part of this 
project, was a titration study of the influenza virus using 2 ferrets infected with a high dose of 
influenza (undiluted stock, inhaled dose of 12,620 TCID50), 2 ferrets infected with a low dose of 
influenza (stock 1:10 dilution, inhaled dose of only 201 TCID50) and 2 control ferrets (sham 
aerosol, PBS only).  Given the large difference in doses and the lack of differences in clinical 
results between the two groups of animals, we chose to move forward with undiluted challenges 
so as not to drop below the median lethal dose (LD50).  The average required dose to infect 
humans with influenza by aerosol challenge is 0.6-3 TCID50.  Fifty-percent ferret infectious dose 
(FID50) is estimated to be as low as 10-30 TCID50 for pre-pandemic H1N1 and 3 plaque-forming 
units (pfu) for a pandemic H1N1.  In hindsight, we could have likely challenged with a 1:10 
stock of virus.  It is possible that by challenging with the undiluted stock, we used an 
overwhelming amount of virus and potentially limited our ability to observe the effect of 
antivirals.  Research has shown in a mouse  model that animals challenged with a low dose (103.5 
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EID50) of influenza A virus can benefit fully from an antiviral that does not protect mice 
challenged with a higher dose (106.8 EID50), and Marriot et al. found similar data in ferrets [36]. 
 From study #2, we concluded that low dose prophylactic treatment with HB36.6 is 
effective at reducing clinical signs of disease in ferrets infected with influenza, but there is little 
to no effect on viral loads.  This is similar but not as pronounced in study #3.  We speculate that, 
in addition to the high dose challenge, this may be related in part to immune responses such as 
cytokine induction that differed in ferrets treated with HB36.6 compared to untreated controls.  
In conclusion, using prophylactic doses of HB36.6 seems to reduce clinical signs of disease in 
ferrets infected with influenza, but has less effect on viral loads.  Further studies are needed to 
determine the timing and dosage for optimal treatment with HB36.6 as a successful therapeutic 
against aerosolized influenza A infection. 
5.1 PROPOSED MODEL 
If this ferret model accurately mimics H1N1 influenza A infection and treatment in 
humans, then this new antiviral could work similarly to oseltamivir (Tamiflu).  Professor Chris 
Del Mar, MD, a member of Cochrane who helped analyze Tamiflu data, expressed his concerns 
with the antiviral saying that it could help people feel better, but does not reduce viral shedding 
[37].  This increases the chances of a public health disaster because people will feel better and 
think that they have cleared the virus, so will be more likely to be out in the community and still 
be able to pass the virus onto others.  HB36.6-treated ferrets in studies #2 and #3 displayed fewer 
clinical symptoms, yet did not show much difference in viral copy numbers at necropsy on days 
3 or 6 PI.  HB36.6 is administered intranasally and has been hypothesized to coat the nasal tract 
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as one mechanism to block infection.  It is possible that the toxicity effect on daily HB36.6-
treated animals in study #4 actually helped to increase viral copy numbers detected in the nasal 
washes instead of blunting the viral infection as intended.   
Cytokine analysis to look at immunologic response throughout the course of infection 
would be helpful in further shaping our proposed model.  Additional studies with larger animal 
numbers also need to be completed to increase sample size and provide statistical significance.  
However, based on this limited data, we propose the following model (Figure 13):  
administration of a prophylactic dose of HB36.6 helps coat the nasal tract beginning in the nares 
and following down the trachea into the lungs; as virus is inhaled it is bound by the antiviral and 
the overall initial inoculum is lessened, decreasing the initial insult to the host; the early clinical 
signs of disease following aerosol infection are thus lessened when compared to untreated 
animals.  However, in the absence of additional treatment, virus that does get inside the animal 
begins to replicate and recruit immune cells, causing activation and an increase in virus 
replication.  Therefore, after the first few days it is no longer possible to see differences in either 
the clinical signs or viral loads in treated or untreated animals.  Repeating study #4 with low-
dose therapeutic treatment of HB36.6 may provide better protection, helping to keep the viral 
burden and clinical signs of disease reduced.  Regardless, it is likely that in the current studies, 
differences in clinical signs of disease are associated with differences in immunologic responses 
exhibited throughout the course of infection. 
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Figure 13. Proposed model for treatment with low dose HB36.6 after aerosol exposure to influenza virus 
A/California/07/09.   
We assume that this ferret model mimics what will happen in human trials.  Untreated and HB36.6-treated (purple 
plus-sign) ferrets showed similar viral titers (red 7-point star) in nasal wash and lung samples.  Treated ferrets 
display fewer signs of disease, which may be associated with reduced immunological responses (green half-moon). 
5.2 PUBLIC HEALTH SIGNIFICANCE 
Influenza virus causes an estimated 250,000-500,000 deaths annually and remains a 
significant public health issue.  When a host is infected with multiple strains of influenza A, gene 
reassortment can occur leading to new subtypes of the virus that cause increased morbidity and 
mortality in the human population [5].  Influenza also has a high evolutionary capacity, which 
quickly leads to drug-resistance against several FDA approved antiviral drugs, as seen with 
oseltamivir (Tamiflu) [3].  The best protection against influenza infection is receiving the annual 
vaccine.  However, due to the current selection for strains that go into the annual vaccine, and the 
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lead time necessary to produce the vaccine annually, the vaccine is not always well-matched or 
effective against the following influenza season.  There are also certain subsets of the population 
that are either unable to receive the vaccine, or are more susceptible to disease, including the 
very young and elderly, immune-compromised individuals, and pregnant women.  Therefore, it 
is pertinent that more effective antivirals, that have not yet induced antiviral resistance, come to 
market.  
Small molecular proteins have great potential for clinical use, as they can help shorten 
disease duration and reduce the risk of influenza-associated complications, as well as death, if 
taken in a timely manner.  Influenza A viruses consist of eight segmented RNA genes that 
encode 12 known proteins: HA, NA, PA, PB1, PB1-F2, PB2, NP, N40, M1 matrix proteins, M2 
ion channel proteins, NS1 and NS2, all of which have potential as drug targets.  Combination 
therapies using antivirals with different mechanisms of action can also be used to achieve greater 
efficacy.  For example, a co-treatment with amantadine + oseltamivir, or favirpiravir + 
oseltamivir has demonstrated better efficacy against H5N1-challenged mice.  Treatment with 
three antiviral drugs, amantadine + ribavirin + oseltamivir, helped reduce mortality in Korean 
patients hospitalized with severe A/H1N1 2009 (pH1N1) [17].  This project explores the use of a 
new HA-binding antiviral protein for group 1 influenza A viruses that can be used on its own or 
as a combination treatment with other anti-influenza drugs.  The advantages of using small 
molecular proteins include that they are typically more stable, less immunogenic, and less costly 
than larger molecular drugs [38].  We hope that these advantages will allow great success in 
using small proteins as anti-influenza treatments and help reduce the morbidity and mortality 
associated with this disease. 
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5.3 FUTURE DIRECTIONS 
Given the high clinical scores in the therapeutically treated ferrets with a high dose of 
HB36.6 compared to untreated controls, a study should be done in the ferret model without viral 
infection to assess toxicity of the antiviral protein.  A second, even broader-binding antiviral 
peptide is currently under development to include protection from group 2 subtypes of influenza 
A by combining a second small protein to work along with HB36.6.  This would allow the 
antiviral to protect from up to 16 different subtypes of influenza as well as drifted and shifted 
genetic variants of the virus.  Additional computationally-designed proteins are being evaluated 
for their ability to inhibit influenza B viruses. 
The Cole lab will further evaluate ferret tissues for cytokine responses following 
experimental influenza infection, comparing antiviral treated and untreated samples.   Several 
new reagents are being evaluated currently for these assays, so that assays will be able to utilize 
blood and serum samples as well as RT-PCR.  The success of this project will allow for better 
detection and understanding of the immunologic responses and specifically cytokine responses 
elicited by influenza infection, and give rise to better reagents for the ferret model.  For example, 
researchers have reported that ferret inflammatory cytokines share a similar specific structure to 
humans, including IFN-γ, TNF-α, IL-8, IL-6, and IL-1β, [32].  However, not many reagents have 
been successfully shown to cross react with the ferret.  The Cole lab has recently partnered with 
the Center of Excellence for Influenza Research at St. Jude Children’s Research Hospital to 
obtain newly developed ferret reagents that will be used in these studies.   
The goal is to continue to monitor cytokine responses by RT-PCR and adapt new assays 
to measure proteins in the periphery (blood and nasal wash samples) so that the translation of 
data between the ferret model and the human is more relevant.  These studies will provide 
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information on the relevance of immune responses elicited in the ferret during influenza 
infection, so that this model can further be used to predict and evaluate how to overcome the 
cytokine storm and reduce fatal outcomes in humans.   
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APPENDIX A: EXPERIMENTAL PROCEDURES 
A.1 VIRUS PROPAGATION 
A.1.1 MDCK and Hela Cell Lines 
• Materials/Reagents: 
1. Madin-Darby Canine Kidney (MDCK) cells (ATCC CCL-34) 
2. HeLa cells (ATCC) 
3. Maintenance Media 
a. 500ml DMEM (1X) 
b. 5ml Penicillin/Streptomycin (10,000 U/ml / 10,000 ug/ml) 
c. 5ml HEPES Buffer (1M stock) 
d. 5ml L-gluamine, 200 mM (100X), if needed 
e. 25ml Heat Inactivated FBS 
f. 5ml Sodium pyruvate, if needed (may already be in DMEM) 
4. Trypsin/EDTA, 0.25% 
5. Phosphate-buffered saline (PBS) (pH 7.2) 
6. Water bath 
7. T75, T75 and T150 flasks with vented cap 
8. 37°C, 5% CO2 incubator 
9. 15ml conical tube 
10. Trypan Blue solution, 0.4% (Sigma, cat. #T8154) 
11. Hemocytometer 
12. 1.5ml cryovials 
13. Freezing media (90% FBS/10% DMSO) 
a. Fetal Bovine Serum (FBS) (Atlanta Biological, Cat. #S11150) 
b. Dimethyl Sulfoxide (DMSO) (Sigma, Cat. #D2650) 
14. Freezing Container, 1°C/hr (NALGENE Cryo, cat. #5100-0001) 
15. Alcohol 
16. -80°C freezer 
17. Liquid nitrogen storage 
• Protocol: 
1. Propagation 
a. Thaw cells from LN2 in 37°C water bath 
b. Resuspend in 10ml maintenance media 
c. Centrifuge for 5 minutes at 400g in a 15ml conical tube 
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d. Dump supernatant in bleach 
e. Resuspend in 8ml maintenance media 
f. Pipette cell suspension into a T25 flask with a vented cap 
g. Incubate for 24-36 hours in 37°C, 5% CO2 incubator 
2. Cell Splitting/Maintenance 
a. Cells should be split 1:10 every 3-4 days 
b. Warm maintenance media and trypsin to 37°C using water bath 
c. Wash cells twice with 10ml room temperature PBS 
d. Add 2ml trypsin (for a T75 flask; 4ml for a T150flask) and tilt flask to 
coat bottom of flask 
e. Place flask in incubator until cells round up and dislodge (5-10mins) when 
the flask is tapped from the side 
f. Resuspend cells in a 5:1 volume of maintenance media: trypsin washing 
residual cells from the flask surface 
g. Move 1:10 volume to a new flask 
h. Incubate flask in 37°C/5% CO2 incubator for 3-4 days 
i. Note: MDCK cells should not be carried for more than 20 passages 
(P20’) for productive influenza replication 
3. Freezing Back Cells 
a. Grow cells to 80-90% confluency (log phase growth) using steps 2b-f 
above 
b. Count viable cells using trypan blue and a hemocytometer 
c. Resuspend cells at 107cells/ml in freezing media 
d. Aliquot 1ml suspensions into cryovials 
e. Place inside a freezing vessel and store -80°C freezer for up to 72hours 
f. After 48-72hours transfer cells to liquid nitrogen (LN2) for long-term 
storage 
 
A.1.2 Influenza H1N1 Virus Egg Infection 
• Materials/Reagents: 
1. Embryonated Chicken Eggs, 9-12 days old 
2. Flashlight 
3. Needle 23 gauge, 1 inch 
4. Needle 18 gauge, 1 inch 
5. Disposable syringe 
6. 50ml centrifuge tube with 70% alcohol  
7. Alcohol wipes 
8. Sterile forceps 
9. Influenza virus 
a. A/California/07/09 (H1N1) at 2.6 x 108 CEID50/ml (BEI Resources cat. 
#NR13663) 
10. Sharps container 
11. Tape 
12. Egg incubator 
• Protocol: 
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1. Candle the eggs everyday starting at D8.  Mark with a pencil the air sac and main 
veins. 
a. Good egg: Observe embryo movement and see intact blood vessels around 
the egg. 
b. Bad egg: Egg has too many white spots, too few veins, or is all black. 
 
2. Inoculation of Influenza virus in embryonated eggs (usually use D11 eggs 
because has given best quality of fluid in the past: high volume of clear liquid). 
a. Prepare the virus inoculum: 10-3 – 10-10, 10 eggs per dilution. 
b. Wipe top of eggs with alcohol wipes, let dry, and punch a small hole in the 
eggshell over the air sac using an 18 gauge, 1 inch needle.  Make sure to 
punch hole close to fluid, so the needle can reach the fluid, and away from 
any major veins. 
c. Aspirate virus inoculum into 1ml syringe with 23 gauge, 1 inch. 
d. Insert the needle into the hole of the egg, pierce the allantoic membrane 
(about 0.5cm deep from egg shell) and inoculate 0.2ml per egg into the 
allantoic cavity. 
i. Change the syringe and needle when finished inoculating eggs in 
each tray or if the needle touches eggshell. 
e. Discard the syringe into a sharps container and seal the punched holes of 
the eggs with tape. 
f. Incubate the inoculated eggs at the appropriate conditions for virus strain. 
i. H1N1: 37°C, >80%RH humidity for 48 hours 
g. After 2 days of incubation remove the eggs from the egg incubator and 
candle to ensure eggs are still good. 
h. Chill the eggs by placing them in a refrigerator (4°C) overnight (at least 12 
hours) or chill at -20°C for 2-3 hours to sacrifice the embryo and harden 
the blood vessels for good fluid harvest. 
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3. Harvesting the infected allantoic fluid 
a. Dip the forceps in 70% alcohol to sterilize and peel off the top of the 
eggshell (open up the air sac). 
b. Insert the 23 gauge, 1 inch needle downward into the allantoic sac. 
c. Draw out the clear allantoic fluid and avoid disturbing the blood vessels 
and yolk sac and place in proper container depending on dilution. 
4. HA/Infectivity Test 
a. Perform an infectivity test to ensure titer.  Usually get a titer >9 log 
EID50/0.2ml in the 10-6 – 10-9 dilutions, depending on virus strain and 
incubation conditions. 
 
A.1.3 Hemagglutination (HA) Assay for Titering Influenza Virus 
• Materials/Reagents: 
1. PBS (pH 7.2) 
2. V-bottom 96-well plate 
3. 5% Turkey red blood cells (TRBC) (Lampire Biological Labs, Pipersville, PA), 
fresh TRBC, less than 2 weeks old 
a. To make 0.5% TRBC: 
i. Spin 1ml TRBC at 650rpm for 5mins in 15ml tube 
ii. Dump supernatant and resuspend in 10mls of PBS 
1. Note: This is enough for two 96-well plates 
4. Multichannel pipette 
5. Influenza virus stocks 
6. Known positive virus for positive control 
7. Trough or reservoir 
• Protocol: 
1. Pipette 50µl room temperature PBS per well in wells B through H 
2. Add 100µl virus to top wells (row A) in triplicate 
a. Needed Controls: 
i. Known positive virus control 
ii. Negative control = PBS in place of virus 
3. Add 50µl of row A to row B 
4. Add 50µl of row B to row C…continue as a 2 fold dilution (serial dilution, 1:2) 
down the plate, changing pipette tips in between each row 
5. When get to row H, remove 50µl and discard so total volume is the same (50µl) 
6. Add 50µl 0.5% TRBC to each well 
7. Agitate plate for 20 sec to mix samples 
8. Incubate for 1 hour at room temperature 
9. Observe agglutination reaction 
a. Button = no agglutination (negative reaction) 
b. No button = agglutination (positive reaction) 
10. Record endpoint HA titer, which is the last dilution to show agglutinations (last 
dilution with a positive reading) 
 
A.1.4 TCID50 Assay 
• Material/Reagents: 
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1. Virus dilution media 
a. 500ml DMEM 
b. 5ml Pen/Strep 
c. 12.5ml Bovine Serum Albumin (BSA) Fraction V, 7.5% in PBS 
i. 7.5g BSA in 100ml PBS 
d. 5ml  HEPES buffer (1M stock) 
2. Viral growth media 
a. 100ml Viral Dilution Media 
b. 0.1ml 1:1000 2mg/ml TPCK-trypsin (2µg/ml) stock added at time of use 
i. Stock: dissolve 20mg TPCK trypsin (type XIII from bovine 
Pancreas) in 10ml dH2O, sterile filtered through 0.2µm membrane, 
store at -20°C 
3. PBS (pH 7.2) 
4. Trypsin-EDTA, 0.25% 
5. MDCK maintenance media 
6. Trypan blue 
7. Hemacytometer 
8. 96-well flat-bottom plate or 96-well v-bottom plate 
9. Microscope 
10. 37°C, 5% CO2 incubator 
• Protocol: 
1. Prepare MDCK cells from a confluent T-75cm2 flask 
a. Remove culture media from confluent T-75 flask 
b. Wash cells twice with 10ml PBS 
c. Add 2ml trypsin-EDTA to monolayer in flask  
d. Place flask in incubator until cells round up and dislodge (5-10mins) when 
the flask is tapped from the side 
e. Add 10mls maintenance media using multichannel pipette and swirl flask 
to get all cells off the sides 
f. Enumerate cell concentration using standard trypan blue and a 
hemocytometer (add 20µl cells + 20µl dye, and load 10µl of mixture onto 
hemocytometer) 
g. Dilute the cells to 3.0 x 105 cells/ml in maintenance media 
h. Dispense 100µl (3.0 x 104 cells/ml into each well of a 96-well plate 
(analyze up to 2 samples per plate) 
i. Incubate plate in a 37°C, 5% CO2 incubator for about 24-30 hours, until a 
confluent monolayer is formed in the bottom of the wells 
j. Once monolayer is present, aspirate media from MDCK cells 
k. Wash cells twice with 200µl of PBS using multichannel pipette and 
remove using aspiration 
l. Add 150µl viral growth media to each well containing cells and set plate 
aside 
2. Set up virus titrations 
a. Obtain new, empty 96-well plate to make virus dilutions 
b. Add 180µl of viral growth media to rows B-H of 96-well plate 
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c. Add 200µl virus sample to row A (sample 1 = columns 1-5; sample 2 = 
columns 6-10; column 11 = known positive control; column 12  = 
negative control, which is 200µl of assay buffer only) 
d. Transfer 20µl of row A to row B and discard tips 
e. Mix 20 times using swirling tip action, transfer 20µl sample from row B to 
row C, and discard tips 
f. Continue the serial dilution down the plate, changing tips in between each 
row 
3. Add virus dilutions to MDCK cells 
a. Using a multichannel pipette, transfer 100µl of each virus dilution to the 
MDCK cells in 96-well plate starting at the lowest concentration in row H, 
and working upwards using the same tips to mix 
b. Incubate plate at 37°C, 5% CO2 incubator overnight 
c. Observe and record cytopathic effect (CPE) daily using the following key: 
i. CPE 0 = no cytopathic effects observes, same as controls 
ii. CPE 1 = monolayer intact, rounded up cells on top monolayer with 
few dead cells 
iii. CPE 2 = many dead cells, but monolayer intact 
iv. CPE 3 = most cells destroyed, but some remnants of monolayer 
observed 
v. CPE 4 = monolayer completely destroyed 
d. Calculate the TCID50 using Reed-Muench method [39] 
 
A.1.5 Hemagglutination Inhibition (HI or HAI) Assay for Detection of Influenza Specific 
Antibodies 
• Materials/Reagents: 
1. See HA assay above for materials/reagents 
a. See HA assay above for preparation of 0.5% TRBC 
2. Prepare 1% TRBC 
a. Spin 1ml TRBC at 650rpm for 5 min in 15ml conical tube 
b. Dump supernatant and resuspend in 10ml PBS for 1% working 
concentration 
3. Water bath 
4. Ferret sera samples 
5. Sterile microcentrifuge tubes 
6. Microcentrifuge 
• Protocol: 
1. Prepare ferret sera 
a. Heat inactivate ferret sera samples in 56°C water bath for 30min 
b. Transfer 50µl heat inactivated sera to new tube 
c. Add 200µl 0.5% TRBC suspension to each sera sample 
d. Incubate the sera: TRBC mixture at room temperature for 30mins, vortex 
tubes every 10mins to mix 
e. Pellet the TRBC in the sera tubes by microcentrifuging at 14,000rpm for 
5sec 
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f. Transfer the sera into a sterile 96-well plate, being careful not to disturb 
the TRBC pellet 
2. Perform HI assay 
a. See plate set-up below 
b. Pipette 50µl room temperature PBS per well in wells B-D and F-H of 96-
well plate using a multichannel pipette and reservoir basin 
c. Add 100µl of each serum sample in duplicate to top wells (row A and E) 
i. Needed Controls: 
1. Known positive antigen control (diluted in duplicate in 
rows A-D) 
2. Negative control = PBS in place of virus (diluted in 
duplicate in rows E-H) 
d. Add 50µl of row A to row B 
e. Add 50µl of row B to row C, and row C to row D (2-fold dilution, 1:2 
serial dilution), changing pipette tips in between each row 
f. Repeat serial dilution for rows E-H 
g. When get to rows D and H, remove 50µl and discard so total volume is the 
same (50µl) in all wells 
h. Dilute H1N1 virus stock to 4 hemagglutination units (HAU) (1:4 dilution) 
i. For 2 plates, dilute 3ml virus in 9ml PBS 
i. Add 50µl diluted virus stock to each well starting with row D and working 
upward to row A, mixing by pipetting, and repeat for rows H-E 
j. Agitate plate for 20sec to mix samples 
k. Incubate for 30min at room temperature 
l. Add 50µl of the 1% TRBC suspension to all wells starting with row H and 
working upward to row A, using new pipettes for each row 
m. Incubate plate for another 30-45 mins at room temperature 
n. Observe agglutination reaction 
i. Button = no agglutination (anti-H1N1 antibodies are present, Ab+; 
previously exposed to influenza) 
ii. No button = agglutination (no antibodies in serum, Ab-; no pre-
exposed to influenza)  
Table 4. Plate Set-up for HI Assay 
 1 2 3 4 5 6 7 8 9 10 11 12 
A S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 +1:10 +1:10 
B           +1:20 +1:20 
C           +1:40 +1:40 
D           +1:80 +1:80 
E S6 S6 S7 S7 S8 S8 S9 S9 S10 S10 -1:10 -1:10 
F           -1:20 -1:20 
G           -1:40 -1:40 
H           -1:80 -1:80 
                    Note: S# = sample # 
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A.2 FERRET CLINICAL SCORING OBSERVATIONS 
 
Note: A score of 0 indicates normal behavior or no display of signs of disease, where a higher clinical score is 
indicative of greater clinical signs of disease. 
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A.3 VIRAL TITER QUANTIFICATION 
A.3.1 RNA Extraction 
1. RNA Isolation from Liquid Samples (Blood, Serum, Supernatant, Nasal Wash) 
a. Materials/Reagents: 
i. TRI Reagent Solution (Ambion, cat. #AM9738) 
ii. PureLink Viral RNA/DNA Kit (Invitrogen, cat. #12280-050) 
iii. 96-100% ethanol 
iv. 70% ethanol 
v. RNase/DNase-free microcentrifuge tubes 
vi. Class II Biological Safety Cabinet (BSC) 
vii. Chloroform (EMD, cat. #CX1055-14) 
viii. RNase Away (Life Technologies, Thermo Scientific, cat. #10328011) 
b. Preparation of reagents: 
i. Add 60ml 96-100% ethanol to wash buffer in kit 
c. Protocol: 
i. Inactivation of samples: 
1. Add 100µl sample to 900µl TriReagent 
2. Mix by inverting or pipetting (DO NOT VORTEX) 
3. Let sit at room temperature for 5 mins 
4. Samples can now be brought out of the RBL by transferring to a 
new sterile Eppendorf tube, spraying the outside of the tubes with 
vesphene, double bagging and removing from the RBL 
5. Store the sample at -80°C in BSL2 or proceed immediately to 
extraction 
ii. Extraction and purification of RNA 
1. If samples were frozen, let thaw at room temperature 
2. Inside BSC, add 200µl chloroform to all samples and invert 
vigorously for 20sec (DO NOT VORTEX) 
3. Let sit at room temperature for 3mins 
4. Centrifuge at 12,000 x g for 15mins at 4°C 
5. Transfer 500µl of the aqueous phase (top clear layer) to a new tube 
6. The rest of the procedure can be performed on a benchtop, clean 
the benchtop and all supplies with RNase Away before proceeding 
7. Add 500µl 70% ethanol to all samples, vortex, and let sit at room 
temperature for 5mins 
8. Transfer the lysate to the viral spin column in a collection tube 
(supplied) in two 500µl increments (viral spin column can hold 
700µl volume max) 
9. Centrifuge at 6800 x g for 1min 
10. Discard the collection tube and place spin column in a new 
collection tube (supplied) 
11. Add 500µl wash buffer with ethanol (prepared above, supplied by 
kit) to all viral spin columns 
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12. Centrifuge at 6800 x g for 1min and discard the flow through 
13. Repeat step 11-12 
14. Discard collection tube and place viral spin column in new 
collection tube 
15. Centrifuge at max speed for 1 min to dry the viral spin column 
16. Place the viral spin column inside a clean Eppendorf tube (supplied 
by kit) 
17. Elute RNA with 40µl sterile RNase-free water (supplied) directly 
to the viral spin column cartridge 
18. Incubate samples at room temperature for 1min 
19. Centrifuge at max speed for 1min 
20. Discard the viral spin column and store the purified viral RNA at 
−80°C 
2. RNA Isolation from Tissue Samples 
a. Materials/Reagents: 
i. TriReagent 
ii. chloroform 
iii. RNeasy Mini Kit (Qiagen, cat. #74104) 
iv. RNase-free DNase Set (cat. #79254) for on-column DNase digestion 
v. DMEM with 2% FBS 
vi. Balance (for measuring tissue weight) 
vii. Tissue Homogenizer (Omni TH) with Omni Tip Plastic Probes 
(Kennesaw, GA) 
viii. 5ml snap-cap tubes 
ix. Sterile forceps and scissors 
x. Vesphene 
xi. 70% ethanol 
xii. Bucket with ice 
xiii. Eppendorf tubes 
xiv. Vortex 
xv. -80°C Freezer 
xvi. Sorvall Legend Micro 17R/21R Centrifuge (Thermo Scientific) 
xvii. Class II Biological Safety Cabinet (BSC) 
b. Protocol: 
i. Homogenize Tissue 
1. Thaw tissue samples on ice and keep on ice throughout process 
2. Pipette 2x the volume (of tissue) of DMEM with 2% FBS (800µl 
media for 0.4g tissue) 
a. Note: For tissues weighing ≤200mg (0.2g), use 400µl 
media 
3. Under BSC, remove tissues from original vials using sterile 
forceps, weigh tissues to ≈400mg (0.4g) using balance and sterile 
scissors 
4. Transfer weighed tissue to 5ml snap-cap tube containing DMEM 
with 2% FBS 
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5. Homogenize each sample in media using a new sterile tip for 
≈10sec until no large clumps of tissue remain 
a. Note: Hold the homogenizer and tube far back in the hood 
and tilt the tube away from you to avoid spraying sample 
out of the hood by accident 
6. Remove the homogenizer tip carefully, disassemble the inner blue 
part from the outer clear part, and place both pieces in a pan of 
vesphene to disinfect 
7. Keep snap-cap tubes with homogenized samples on ice until all 
samples are finished 
ii. Inactivate Virus 
1. Add 900µl TriReagent to sterile eppendorf tubes and transfer 
100µl of each homogenized tissue to a tube containing TriReagent 
2. Vortex all samples very well and let sit at room temperature for 
5min with frequent vortexing until no visible clumps of cells are 
left 
3. After incubation, clean out hood, place down a clean hood liner, 
and transfer sample to a new sterile eppendorf tube 
4. Keep the samples at 4°C if you are not going to continue to the 
next step immediately or store them in -80°C freezer 
iii. Extract RNA 
1. Turn on Themocycler to 4°C 
2. If samples are frozen, thaw to room temperature 
3. In BSC, add 200µl chloroform to each tube and invert vigorously 
for 20sec (DO NOT VORTEX) 
4. Let sit at room temperature for 3min 
5. Centrifuge at 12,000 x g for 15min at 4°C 
6. Transfer 500µl of aqueous phase (clear top layer) to a clean tube 
7. The remaining steps can be performed on a benchtop cleaned with 
RNase Away Reagent; remove tubes from BSC and clean hood 
with vesphene 
8. Add 1 volume (500µl) 70% ethanol to each lysate and mix well by 
pipetting 
9. Transfer up to 700µl of sample at a time to RNeasy Mini Spin 
column inside a 2ml collection tube (supplied in kit) 
10. Centrifuge at >8000 x g for 15sec 
11. Discard flow through and repeat with remaining sample 
12. Add 350µl Buffer RW1 to spin column 
13. Centrifuge at max speed for 30sec and discard flow-through 
14. Add 10µl DNase 1 stock solution to 70µl Buffer RDD (Note: This 
calculation is per reaction. Multiply volumes for more samples.), 
mix by inverting tube, and briefly centrifuge 
15. Add 80µl DNase 1 – Buffer RDD mixture directly to spin column 
membrane and incubate at room temperature for 15mins 
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16. Add 500µl Buffer RPE to spin column, centrifuge at max speed for 
30sec and discard flow-through 
17. Repeat step 16 
18. Place spin column in a new collection tube (supplied in kit) and 
centrifuge at full speed for 1min to dry the membrane 
19. Place spin column in a new 1.5ml collection tube with cap 
(supplied in kit), add 40µl nuclease-free water directly to the spin 
column membrane, and centrifuge at max speed for 1min to elute 
RNA 
20. Store samples in -80°C freezer 
 
A.3.2 PCR for Viral Titers [30, 40] 
1. Material/Reagents: 
a. Superscript III Platinum One-Step qRT-PCR Kit with ROX (Invitrogen, 
Carlsbad, CA, cat. #11745-100) 
b. MicroAmp Optical 96-Well Reaction Plate (Applied Biosystems, Life 
Technologies, Thermo Scientific, cat. #4306737) 
c. MicroAmp Optical Adhesive Film (Applied Biosystems, Thermo Scientific, 
cat. #4311971) 
d. 7900HT Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA) 
e. RNase/DNase-free microcentrifuge tubes 
f. Nuclease-free water 
g. Swine Influenza A (H1N1) real-time RT-PCR Assay (BEI Resources, NR-15577) 
h. Standard Curve with known virus titers 
2. Preparation of Reagents: 
a. Nucleic acids extracted from Swine Influenza A (H1N1) Positive Control (NR-
15590), and Novel H1N1 2009 (Swine) Influenza A (NR-15627) should be 
diluted 1:10 prior to use as template in the assay 
b. Working stock aliquots of the primers and probes should be made at 
concentrations of 40µM (primers) and 10µM (probes) by adding 500µl nuclease-
free water to each 
 
Table 5. Influenza PCR Primers and Probes 
Primers and Probes Catalog # Sequence 
*InfA Probe NR-15578 TGC AGT CCT CGC TCA CTG GGC ACG 
InfA Forward NR-15579 GAC CRA TCC TGT CAC CTC TGA C 
InfA Reverse NR-15580 AGG GCA TTY TGG ACA AAK CGT CTA 
**Sw H1 Probe NR-15584 CA GAA TAT ACA “T”CC RGT CAC AAT TGG ARA A 
Sw H1 Forward NR-15585 GTG CTA TAA ACA CCA GCC TYC CA 
Sw H1 Reverse NR-15586 CGG GAT ATT CCT TAA TCC TGT RGC 
*At the 5’end, TaqMan® probes are marked with the reporter molecule 6-carboxyfluorescein (FAM) and at the 3’ 
end with the quencher, Blackhole Quencher 1 (BHQ1) (Biosearch Technologies, Inc., Novato, CA) [41].  
**Taqman® probes are labeled at the 5'-end with the reporter molecule 6-carboxyfluorescein (FAM) and quenched 
internally at a modified “T” residue with BHQ1, with a modified 3’- end to prevent probe extension by Taq 
polymerase [41].  
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3. Protocol: 
a. Thaw RNA samples and PCR reagents on ice, keep on ice throughout procedure 
b. Label one microcentrifuge tube for the master mix 
c. All samples, standards and controls should be run in duplicate 
d. Prepare master mix according to table below: 
 
Table 6. PCR Master Mix 
Reagent Volume of Reagent per Reaction 
Forward Primer N x 0.5µl 
Reverse Primer N x 0.5µl 
Probe* N x 0.5µl 
Superscript Taq Mix N x 0.5µl 
2X PCR Master Mix N x 12.5µl 
Nuclease-free Water N x 5.5µl 
Total Volume N x 20µl 
Note: N = number of samples, controls, and standards, in duplicate; * 6-
carboxyfluorescein (6-FAM) probe must be protected from light 
 
e. After adding water last, mix master mix by pipetting (DO NOT VORTEX) 
f. Add 20µl master mix to all needed wells of a 96-well plate 
g. Add 5µl of each unknown sample, standard or control to each well 
i. Needed controls: 
1. No Template Control (NTC) containing all reagents except an 
RNA sample, which is replaced with nuclease-free water 
2. Positive Controls containing master mix and known positive virus 
samples: Swine Influenza A (H1N1) Positive Control (NR-15590) 
and the Novel H1N1 2009 (Swine) Influenza A Positive Control 
(NR-15627) should be included in each run for all primer and 
probe sets 
h. Wearing gloves, smooth a clear adhesive cover over the 96-well PCR plate using 
the brown tool 
i. Place foam cover on top of clear adhesive cover and take plate to PCR machine 
on ice 
j. Set up the PCR machine using the parameters in the table below: 
i. Internal control = ROX 
ii. Detector = FAM channel 
iii. Sample volume = 25 
 
Table 7. PCR Machine Parameters for Influenza Detection 
Reverse Transcription 50°C for 30 min 
Taq Inhibitor Activation 95°C for 2 min 
PCR Amplification (40 cycles) 
Denature/Anneal 
95°C for 15 sec 
55°C for 30 sec 
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A.3.3 Making Standard Curve 
1. Material/Reagents: 
a. Virus stock with a known high titer 
i. A/California/07/2009 (BEI Resources, cat. #NR-13663) pandemic H1N1 
virus (original titer: 2.8 x 108 CEID50/ml) 
ii. A/California/04/09 (gift provided by Dr. Stacy Schultz-Cherry, St. Jude 
Children’s Research Hospital) pandemic H1N1 virus (original titer: 108.25 
TCID50/ml) 
b. Need all reagents/materials from RNA isolation from liquid samples and PCR 
protocols above 
2. Protocol: 
a. Obtain H1N1 virus stock of known titer in TCID50/ml 
b. Add 100µl virus stock sample to 900µl TriReagent in six replicates (want a lot of 
sample so can make a lot of dilutions and aliquot) 
c. Perform RNA extraction procedure for liquid samples and elute RNA in 40µl 
nuclease-free water 
d. Combine all six replicates together (40µl x 6 ≈ 240µl) 
e. Make 10-fold dilutions with nuclease-free water starting with 1:10 (10-1) and 
going down to 10-8 
f. Run dilution PCR in duplicate against the remaining standard stock 
i. Note: Make sure to include a NTC 
g. After PCR is complete, check the new standard against the old standard for 
accuracy 
h. Calculate new standard quantities based off the original known virus titer 
(TCID50/ml) 
 
Table 8. H1N1 Standard Information 
Standard Amy’s Standard Quantity Allison’s Standard Quantity 
10-1 700000 220000 
10-2 70000 22000 
10-3 7000 2200 
10-4 700 220 
10-5 70 22 
10-6 7 2.2 
 
A.4 CYTOKINE DETECTION 
A.4.1 ELISA 
• Materials/Reagents: 
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1. Capture Antibody: Monoclonal Anti-Ferret Interferon Gamma, Clone 4A4B7 
(BEI Resources, cat. #NR-4492) 
2. Detection Antibody: Monoclonal Anti-Ferret Interferon Gamma, Clone 
1H1H12 (BEI Resources, cat. #NR-4493) 
3. Secondary Antibody: Goat Anti-Ferret IgG IgA IgM Antibody, peroxidase 
conjugated (Rockland Immunochemicals Inc., Limerick, PA) 
4. Ferret serum and blood samples 
5. 96-well flab-bottom Immulon 2HB 
6. 1X PBS 
7. 0.5% Tween-20 
8. TM Blue, soluble form 
9. 1 N H2SO4 
10. Blocking Solution: 1% BSA in PBS 
11. Multi-pipetter 
12. Plate reader PowerWave XS (BioTek) and SpectraMax L 
• Preparation of Reagents (All Procedures): 
1. 0.05M Bicarbonate Buffer pH 9.6 
Solution A: 5.29 g Na2CO3 in 1000 ml dH2O 
Solution B: 4.20 g NaHCO3 in 1000 ml dH2O 
*Stir Solution A into Solution B until a pH of 9.6 is obtained 
 2.  1% BSA in PBS (Blocking Solution)  
  0.5 g BSA 
  50 ml of 1X PBS 
  *Let stir for at least 10 min; can store for several days at 4°C 
3. 1X PBS/0.05%Tween-20 
500µl Tween-20 in 100ml 1X PBS 
*Use stir-plate to mix solution 
 4.  TM Blue 
  Use undiluted; bring to room temperature before using 
5.  1 N H2SO4 Stop Solution 
    27.8ml concentrated sulfuric acid (95%-98% pure) in 972.2ml dH20 
• Preparation of Reagents (Procedure #1 Only): 
6.  Antigen 
Use 20µl recombinant ferret IFN-gamma in 880µl 0.05M bicarbonate 
buffer 
 7.  Primary Antibody (150µl total volume per antibody type) 
  MAb1: 3µl in 147µl blocking solution 
per well, 0.05µl, 0.025µl, 0.0125µl, 0.00625µl 
MAb2: same as MAb1 
Serum (PAb): 15µl in 135µl blocking solution 
Use dilutions 1:10, 1:20, 1:40, 1:80 
Prebleed: 15µl in 135µl blocking solution 
Use dilutions 1:10, 1:20, and two blanks (only blocking solution) 
8.  Secondary Antibody 
  Use a 1:10,000 dilution: 1µl in 10ml of blocking solution 
• Preparation of Reagents (Procedure #2 Only): 
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6.  Primary Antibody (Monoclonal Antibody 4A4B7) 
Add 9µl MAb to 891µl bicarbonate buffer 
7.  Antigen 
Add 3µl recombinant ferret IFN-gamma to 147µl blocking solution 
Serum (PAb): 15µl in 135µl blocking solution 
Use dilutions 1:10 and 1:20 
8.  Secondary Antibody (Monoclonal Antibody 1H1H12) 
  Add 9µl MAb to 891µl blocking solution 
9.  Anti-ferret -IgG, -IgM -IgA Antibody  
Use dilution 1:10,000 for all wells = 1µl in 9,999µl (10ml) of blocking 
solution 
• INF-γ ELISA Procedure #1: 
1. Obtain a 96-well Immulon 2HB flat-bottom ELISA plate and coat 50µl/well 
with recombinant ferret IFN-g antigen overnight (at least 12-16 hours) at 4°C 
2. Remove the coating solution by dumping the liquid in a sink and patting the 
plate on a paper towel to remove the remaining liquid 
3. Wash wells twice with 200 µl 1X PBS 
4. Block the wells with 150 µl of 1% BSA in PBS and incubate for one hour at 
37°C  
5. Empty wells and blot dry, but do not wash them 
6. Dilute the influenza A virus serum (PAb from repository), monoclonal Ab, 
and prebleed (including two blanks of only blocking solution) from ferrets to 
its proper amounts and add 50 µl per wells 
7. Wash plate 5 times with PBS/0.5% Tween-20 and blot dry 
8. Add 50 µl/well secondary anti-ferret-IgG, -IgM -IgA antibody (if already 
peroxidase-labeled) and incubate for one hour at room temperature 
9. Wash wells 5 times with PBS/0.5% Tween-20 and blot dry 
10. Add the substrate, 200 µl of TMB, to each well by putting 4 ml in a conical 
tube for easier access, and let plate shake for 15-20 minutes at room 
temperature  
11. Stop color development with 50 µl per well of 1 normal H2SO4 
12. Measure the color change using an automated plate reader at the needed 
specific wavelength, 450nm 
• INF-γ ELISA Procedure #2: 
1. Obtain a 96-well Immulon 2HB flat-bottom ELISA plate and coat 100µl/well 
with monoclonal antibody A (4A4B7) overnight (at least 12-16 hours) at 4°C 
2. Remove the coating solution by dumping the liquid in a sink and patting the 
plate on a paper towel to remove the remaining liquid 
3. Wash wells twice with 200µl 1X PBS 
4. Block the wells with 200µl of 1% BSA in PBS and incubate for one hour at 
37°C  
5. Empty wells and blot dry, but do not wash them 
6. Dilute the influenza A virus serum (PAb from repository), and recombinant 
ferret gamma IFN antigen from ferrets to its proper amounts and add 50µl per 
wells, letting sit for 1 hour at 37°C 
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7. Wash plate 5 times with 200µl PBS/0.5% Tween-20 and blot dry 
8. Add 100µl second monoclonal antibody B (1H1H12) for one hour at 37°C 
9. Wash 5 times with 200µl PBS/0.5% Tween-20 and blot dry 
10. Add 50µl/well anti-ferret-IgG, -IgM -IgA antibody (if already peroxidase-
labeled) and incubate for one hour at room temperature 
11. Wash wells 5 times with PBS/0.5% Tween-20 and blot dry 
12. Add the substrate, 200µl of TMB, to each well by putting 4 ml in a conical 
tube for easier access, and let plate shake for 20 minutes at room temperature  
13. Stop color development with 50µl/well of 1 normal H2SO4 
14. Measure the color change using an automated plate reader at the needed 
specific wavelength, 450nm 
• Calculations for Procedure #1: 
 A.  Antigen 
  --Stock = 0.1mg/ml 
--50µl x 18 wells = 900µl total volume 
--0.011µg x 18 wells = 0.198 ≈ 0.2µg  
--0.2µg = 20µl 
--20µl added to 880µl 0.05M bicarbonate buffer 
  
 B.  Monoclonal Antibodies 
  --Stock = 0.1mg/ml = 0.1µg/µl 
--Top well concentration = 0.05: 1µl MAb in 50µl total volume, so begin 
with 3µl MAb added to 147µl blocking solution (A) 
--Concentration 0.025: take 75µl A and add 75µl blocking solution (B) 
--Concentration 0.0125: take 75µl B and add 75µl blocking solution (C) 
--Concentration 0.00625: take 75µl C and add 75µl blocking solution (D) 
 C.  PAb (Serum) 
--start with a 1:10 dilution = 15µl in 150 total volume = 15µl serum added 
to 135µl blocking solution (A) 
--1:20 dilution: take 75µl A and add 75µl blocking solution (B) 
--1:40 dilution: take 75µl B and add 75µl blocking solution (C) 
--1:80 dilution: take 75µl C and add 75µl blocking solution (D) 
 D.  Prebleed ferret 
--start with a 1:10 dilution = 15µl in 150 total volume = 15µl prebleed 
added to 135 µl blocking solution (A) 
--1:20 dilution: take 75µl A and add 75µl blocking solution (B) 
• Calculations for Procedure #2: 
 A.  Monoclonal Antibody A (4A4B7) 
  --Stock = 0.1mg/ml = 0.1µg/µl 
--0.1µg/well x 9 wells = 0.9µg = 9 µl 
--100µl/well x 9 wells = 900µl total volume 
--Add 9µl MAb to 891µl bicarbonate buffer 
 B.  Antigen 
  --Stock = 0.1mg/ml = 0.1µg/µl 
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--Want 0.1µg/well in 50µl/well 
--1µl/well antigen + 49µl/well blocking solution 
--0.1µg antigen x 3 wells = 0.3µg = 3 µl antigen 
--Add 3µl antigen to 147µl blocking solution 
 C.  PAb (Serum) 
--Start with a 1:10 dilution = 15µl in 150 total volume = 15µl serum added 
to 135µl blocking solution (A) 
--1:20 dilution: take 75µl A and add 75µl blocking solution (B) 
D.  Monoclonal Antibody B (1H1H12) 
  --Stock = 0.1mg/ml = 0.1µg/µl 
--0.1µg/well x 9 wells = 0.9µg = 9µl 
--100µl/well x 9 wells = 900µl total volume 
--Add 9µl MAb to 891µl blocking solution 
 
A.4.2 PCR 
1. RNA Extraction  
a. RNeasy Mini Kit with on-column DNase Digestion  
i. Materials/Reagents: 
1. RNeasy Mini Kit (Qiagen, cat. #774104) 
2. RNase-Free DNase Set (Qiagen, cat. #79254) 
3. Tissue Homogenizer 
4. Eppendorf centrifuge (5415D) 
5. Micropipettes 
6. Ethanol 
7. RNase/DNase-free 1.5ml snap cap tube 
8. Spectrophotometer (NanoDrop, ND-1000) 
ii. Protocol: 
1. Disrupt the tissue (using no more than 30mg) and homogenize the 
lysate in Buffer RLT.  Centrifuge the lysate for 3 min at maximum 
speed. Carefully pipette out the supernatant into new 
microcentrifuge tube. 
2. Add 1 volume of 70% ethanol to the lysate and mix well by 
pipetting (DO NOT CENTRIFUGE). 
3. Transfer up to 700µl of the sample to an RNeasy Mini spin column 
placed in a 2ml collection tube (supplied by kit).  Close the lid and 
centrifuge for 15 sec at >8000 x g.  Discard the flow-through. 
4. Add 350µl Buffer RW1 to the RNeasy spin column, close the lid, 
and centrifuge for 15 sec at >8000 x g.  Discard the flow-though. 
5. Add 10µl DNase I stock solution to 70µl Buffer RDD.  Mix by 
gently inverting tube and centrifuge briefly. 
6. Add 80µl DNase I incubation mix (made above, step 5) directly to 
the spin column membrane and let sit on bench top for 15 mins 
(20-30°C). 
7. Add 350µl Buffer RW1 to the RNeasy spin column, close the lid, 
and centrifuge for 15 sec at >8000 x g.  Discard the flow-though. 
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8. Add 500µl Buffer RPE to RNeasy spin column, close the lid, and 
centrifuge for 15 sec at >8000 x g.  Discard the flow-though. 
9. Repeat Step 8. 
10. Place RNeasy spin column in a new 2ml collection tube (supplied 
by kit) and centrifuge for 1 min at max speed to dry the membrane. 
11. Place the RNeasy spin column inside a new 1.5ml snap cap tube 
(supplied). Add 30-50µl RNase-free water directly to the spin 
column membrane, close the lid, and centrifuge for 1 min at max 
speed to elute the RNA. 
12. If the expected yield of RNA is >30µg, repeat steps 8-11 using 
another 30-50µl RNase-fee water.  If a high RNA concentration is 
required, use elute from step 7 to repeat through step 11. 
13. Nanodrop for RNA purity and concentration. 
b. Invitrogen PureLink Viral RNA/DNA Kit 
i. Materials/Reagents: 
1. PureLink Viral RNA/DNA Kit (Invitrogen, cat. #12280-050) 
2. 15ml conical tube 
3. 96-100% ethanol 
4. Nuclease-free microcentrifuge tubes 
5. Biological Safety Cabinet II (BSC) 
6. RNase Away Reagent (Life Technologies, Thermo Scientific, 
cat. #10328011) 
7. -20°C and -80°C freezers 
ii. Preparation of reagents: 
1. Add 60ml 96-100% ethanol to wash buffer in kit 
2. Add 310µl nuclease-free water to carrier RNA (this makes a 
1µg/µl solution), mix, aliquot, and store at -20°C 
iii. Protocol: 
1. Prepare lysis buffer with carrier RNA 
a. N x 0.21ml (volume lysis buffer/reaction) = A ml lysis 
buffer 
b. A ml x 28µl//ml = B µl carrier RNA stock solution 
c. In a sterile 15ml conical tube add calculated volumes of 
carrier stock solution (B) to the lysis buffer (A) and mix by 
pipetting (do not vortex) 
d. Store solution at 4°C and use buffer within 1 hour 
2. Let frozen samples thaw on ice 
3. Add 25µl Proteinase K in a sterile microcentrifuge tube 
4. Add 200µl RNA sample into the tube containing the Proteinase K 
5. Inside BSC, add 200µl lysis buffer with carrier RNA  
6. Vortex all samples for 15sec, then the rest of the procedure can be 
performed on the benchtop 
7. Incubate samples in 56°C water bath for 15mins 
8. Add 250µl 96-100% ethanol to all samples, vortex, and let sit at 
room temperature for 5mins 
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9. Transfer the lysate to the viral spin column in a collection tube 
(supplied) (viral spin column can hold 700µl volume max) 
10. Centrifuge at 6800 x g for 1min 
11. Discard the collection tube and place spin column in a new 
collection tube (supplied) 
12. Add 500µl wash buffer with ethanol (prepared above, supplied by 
kit) to all viral spin columns 
13. Centrifuge at 6800 x g for 1min and discard the flow through 
14. Repeat step 11-12 
15. Discard collection tube and place viral spin column in new 
collection tube 
16. Centrifuge at max speed for 1 min to dry the viral spin column 
17. Place the viral spin column inside a clean Eppendorf tube (supplied 
by kit) 
18. Elute RNA with 40µl sterile RNase-free water (supplied) directly 
to the viral spin column cartridge 
19. Incubate samples at room temperature for 1min 
20. Centrifuge at max speed for 1min 
21. Discard the viral spin column and store the purified viral RNA at 
−80°C 
c. QIAamp Viral RNA Mini Kit 
i. Materials/Reagents: 
1. QIAamp Viral RNA Mini Kit (Qiagen, cat. #52904) 
2. 15ml conical tube 
3. 96-100% ethanol 
4. 1.5ml nuclease-free microcentrifuge tubes 
5. Biological Safety Cabinet II (BSC) 
6. RNase Away Reagent 
7. -20°C and -80°C freezers 
8. Nasal wash samples 
9. 80°C incubator 
ii. Preparation of reagents: 
1. Add 25ml 96-100% ethanol to Buffer AW1 in kit (44ml total 
volume) 
2. Add 30ml 96-100% ethanol to Buffer AW2 in kit (43ml total 
volume) 
3. Add 310µl Buffer AVE to carrier RNA (this makes a 1µg/µl 
solution), mix, aliquot, and store at -20°C (do not freeze-thaw the 
aliquots more than 3 times) 
4. Check Buffer AVL for precipitate and if needed, incubate at 80°C 
until dissolved 
iii. Protocol: 
1. Prepare Buffer AVL with carrier RNA 
a. N x 0.56ml (volume Buffer AVL/reaction) = A ml Buffer 
AVL 
b. A ml x 10µl/ml = B µl carrier RNA 
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c. In a sterile 15ml conical tube add calculated volumes of 
carrier stock solution (B) to Buffer AVL (A) and mix by 
inverting tube 10 times (do not vortex) 
d. Buffer AVL with carrier RNA should be prepared fresh 
e. This solution is stable at 2-8°C for up to 48 hours, but will 
develop a precipitate that must be dissolved at 80°C for 
≤5min before use (frequent warming and extended 
incubation can cause degradation of carrier RNA leading to 
false-negative results, especially in low titer samples) 
2. Add 560µl Buffer AVL with carrier RNA into sterile 
microcentrifuge tube 
a. For sample volumes >140µl increase the amount of Buffer 
AVL with carrier RNA proportionally and use larger tubes 
(e.g. 280µl sample requires 1120µl Buffer AVL with 
carrier RNA) 
3. Add 140µl sample to each tube and mix by vortexing for 15sec 
4. Incubate at room temperature for 10mins and centrifuge briefly to 
remove drops from inside the lid 
5. Add 560µl 96-100% ethanol to the sample, mix by pulse-vortexing 
for 15sec, and centrifuge briefly 
a. For sample volumes >140µl, increased amount of ethanol 
proportionally (e.g. 280µl sample requires 1120µl ethanol) 
6. Add 630µl solution from step 5 to the QIAamp Mini column in a 
collection tube (supplied) 
7. Centrifuge at 6000 x g (8000rpm) for 1min 
8. Place mini column in a new collection tube and discard the old 
collection tube 
a. If the solution has not completely passed through the 
membrane, centrifuge again at a higher speed 
9. Repeat steps 6-8 until all solution has passed through column 
membrane 
10. Add 500µl Buffer AW1 to each sample 
a. Do not need to increase this volume for samples >140µl 
11. Centrifuge at 6000 x g (8000rpm) for 1 min 
12. Place mini column in a new collection tube and discard the old 
tube 
13. Add 500µl Buffer AW2 to each sample 
14. Centrifuge at full speed for 3mins 
15. Dump flow-through and centrifuge at full speed for 1min to dry 
column 
16. Place mini column in a clean 1.5ml microcentrifuge tube, add 60µl 
Buffer AVE to each sample 
17. Incubate at room temperature for 1min 
18. Centrifuge at 6000 x g (8000rpm) for 1min to elute RNA 
19. Store extracted sample at -80°C for up to 1 year 
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2. cDNA Synthesis for semi-quantitative RT-PCR 
a. Maxima First Strand cDNA Synthesis Kit 
i. Materials/Reagents: 
1. Maxima First Strand cDNA Synthesis Kit (Thermo Scientific, cat. 
#K1642) 
2. PCR machine (MJ Research, Peltier Thermal Cycler (PCT)-200) 
3. Eppendorf Centrifuge (5415D) 
4. RNase/DNase-free 1.5ml snap cap tubes 
5. RNase/DNase-free 0.2ml omnitubes with flat cap (Thermo 
Scientific, cat. #HBTC6202N) 
ii. Protocol: 
1. Thaw (on ice), mix and briefly centrifuge the components of the 
kit, storing them on ice for the duration of the procedure. 
2. Into a sterile 1.5ml tube on ice, add: 
 
Table 9. cDNA Master Mix 
Reagent Volume 
5X Reaction Mix 4µl 
Maxima Enzyme Mix 2µl 
Template RNA 1µg 
Nuclease-free water ? µl (adjusted to make total volume 20µl) 
Total Volume 20µl 
 
3. Mix gently, centrifuge, and incubate for 10 mins at 25°C followed 
by 15 mins at 50°C (reaction) and terminate by heating for 5 mins 
at 85°C. 
a. Note: For RNA templates greater than 1µg, prolong the 
reaction time to 30 mins.  For GC-rich RNA templates, or 
templates that have a large amount of secondary structure, 
increase the reaction temperature to 65°C. 
4. The cDNA product can be used directly in qPCR or stored at 
−80°C.  Avoid freeze/thaw cycles of cDNA. 
5. Controls needed to verify the results of of the first strand cDNA 
synthesis: 
a. Reverse Transcriptase minus (RT-) negative control should 
contain every reagent for the reverse transcription reaction 
except for the Maxima Enzyme Mix.  This control will help 
assess genomic DNA contamination of the RNA sample. 
b. No Template Control (NTC) should contain every reagent 
for the reverse transcription reaction except the RNA 
template, which should be replaced with Nuclease-free 
water.  This control will help assess reagent contamination. 
b. Maxima First Strand cDNA Synthesis with dsDNase Kit 
i. Materials/Reagents: 
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1. Maxima First Strand cDNA Synthesis Kit for RT-qPCR with 
dsDNase (Thermo Scientific, cat. #K1672) 
2. PCR machine (MJ Research, Peltier Thermal Cycler (PCT)-200) 
3. Eppendorf centrifuge (5415D) 
4. RNase/DNase-free 1.5ml snap cap tubes 
5. RNase/DNase-free 0.2ml omnitubes with flat cap (Thermo 
Scientific, cat. #HBTC6202N) 
6. 37°C water bath 
ii. Protocol: 
1. Thaw (on ice), mix and briefly centrifuge the components of the 
kit, storing them on ice for the duration of the procedure 
2. Into a sterile 0.2ml tube on ice, add:  
Table 10. Addition of dsDNase to RNA Template 
Reagent Volume 
10X dsDNase Buffer 1µl 
dsDNase 1µl 
Template RNA 1pg-5µg 
Nuclease-free water ? µl (adjusted to make total volume 10µl) 
Total Volume 10µl 
 
3. Mix gently, centrifuge, and incubate for 2 mins in 37°C water bath 
4. Chill on ice, briefly centrifuge, and place on ice 
5. Add the following to the same tube: 
 
Table 11. Addition of cDNA Components to RNA Template 
Reagent Volume 
5X Reaction Mix 4µl 
Maxima Enzyme Mix 2µl 
Nuclease-free water ? µl 
Total Volume 10µl 
 
6. Gently mix and centrifuge 
7. In a PCR machine, incubate at 25°C for 10min, 50°C for 15min 
(reaction) and terminate at 85°C for 5min 
a. For RNA templates >1µg increase reaction time to 30min 
b. For GC-rich RNA templates or templates with large 
amount secondary structure increase reaction temp to 65°C 
8. The cDNA product can be used directly in qPCR or stored at 
−80°C.  Avoid freeze/thaw cycles of cDNA. 
9. Controls needed to verify the results of the first strand cDNA 
synthesis: 
a. Reverse Transcriptase minus (RT-) negative control should 
contain every reagent for the reverse transcription reaction 
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except Maxima Enzyme Mix, which is replaced with 
nuclease-free water.  This control will help assess genomic 
DNA contamination of the RNA sample. 
b. No Template Control (NTC) should contain every reagent 
for the reverse transcription reaction except the RNA 
template, which should be replaced with Nuclease-free 
water.  This control will help assess reagent contamination. 
3. PCR: Maxima SYBR Green/ROX qPCR Master Mix (2x) (Thermo Scientific, cat. 
#K0221) [26, 42] 
a. Materials/Reagents: 
i. Maxima SYBR Green/ROX qPCR Master Mix (2X) (Thermo Scientific, 
cat. # K0221) 
ii. RNase Away (Life Technologies, Thermo Scientific, cat. #10328011) 
iii. MicroAmp Optical 96-Well Reaction Plate (Applied Biosystems, Life 
Technologies, Thermo Scientific, cat. #4306737) 
iv. MicroAmp Optical Adhesive Film (Applied Biosystems, Thermo 
Scientific, cat. #4311971) 
v. Primers: IFN-γ, TNF-α, IL-10, GAPDH (Integrated DNA Technologies, 
Coralville, IA) 
 
Table 12. Cytokine Ferret Primers 
Primers Sequence (5’>3’) 
IFN-γ Forward CCATCAAGGAAGACATGCTTGTCAGG 
IFN-γ Reverse CTGGACCTGCAGATCATTCACAGGAA 
TNF-α Forward TGGAGCTGACAGACAACCAGCTAA 
TNF-α Reverse TGATGGTGTGGGTAAGGAGCACAT 
IL-10 Forward TCCTTGCTGGAGGACTTTAAGGGT 
IL-10 Reverse TCCACCGCCTTGCTCTTATTCTCA 
GAPDH Forward AACA TCA TCCCTGCTTCCACTGGT 
GAPDH Reverse TGTTGAAGTCGCAGGAGACAACCT 
 
b. Protocol: 
iv. Thaw (on ice), gently vortex and briefly centrifuge all reagents 
v. Prepare a PCR reaction master mix by adding the following components 
(except template DNA) into a sterile snap cap tube at room temperature: 
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Table 13. PCR Reagents 
Reagent Volume of Reagent Added per Reaction 
Maxima SYBR Green 2X 12.5µl 
Forward Primer 2µl (0.8µM) 
Reverse Primer 2µl (0.8µM) 
Nuclease-Free Water Up to 25µl 
Template cDNA ≤500ng 
Total Volume N x 25µl 
Note: PCR reaction mix is made for each primer set. N = number of samples/ 
reactions, including controls. 
 
vi. Needed Controls: 
1. No Template Control (NTC) containing all components except 
template DNA, which is replaced with Nuclease-free water.  This 
control is important to assess reagent contamination or primer 
degradation. 
2. Reverse Transcriptase Minus (RT-) control containing all 
components except Maxima SYBR Green (2x).  This control is 
important for assessing RNA sample contamination with genomic 
DNA. 
vii. Mix the PCR reaction mix and dispense into the needed wells of a PCR 
plate 
viii. Add Template DNA (≤500ng/reaction) to the appropriate PCR plate wells 
containing the master mix 
1. Note: For two-step RT-qPCR, the volume of cDNA added from 
the RT reaction should not exceed 10% of the final PCR volume 
ix. Gently mix the reactions in the wells (DO NOT VORTEX) without 
creating bubbles, as these will interfere with fluorescence detection, and 
centrifuge briefly if needed 
x. Program the thermal cycler according to the instructions below, place the 
PCR plate inside the machine, and start the program 
 
Table 14. Gene Expression Program 
Optional: UDG pre-treatment 50°C for 2 min 
Initial Denaturation 95°C for 10 min 
 
PCR Amplification (40 cycles) 
95°C for 15 sec 
60°C for 30 sec 
72°C for 30 sec 
Note: SYBR Green (detector) data should be collected during the 72°C extension step 
 
xi. Expression levels should be normalized to Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) and calculated as fold change compared to day 
0 ferrets based on the ∆∆Ct method 
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xii. The ∆Ct is calculated by subtracting the gene of interest at each time point 
from the GAPDH Ct value.  Then fold change is calculated by subtracting 
the day 0 ∆Ct values from the subsequent days ∆Ct values.  The formula: 
fold change = 2−∆∆Ct is then used to obtain absolute values [31] 
A.4.3 Blood Processing 
1. Materials/Reagents: 
a. Blood sample 
b. Lymphoprep (Stemcell, cat. #07861) 
c. 50ml SepMate tube (Stemcell, cat. #15470) 
d. 50mL conical tube (Fisher, cat. #1443222) 
e. PBS + 2% FBS 
i. Dulbecco’s Phosphate Buffered Saline (D-PBS) (Fisher, cat. 
#SH3025801) 
ii. Fetal Bovine Serum (Atlanta Biological, Cat. #S11150) 
f. Sorvall Legend RT+ Centrifuge (Thermo Scientific, cat. #75004377) 
g. Trypan Blue (Fisher, cat. #SV3008401) 
h. Hemacytometer 
i. Microscope (Olympus CKX41) 
j. 2mL Cryovials (Fisher, cat. #033377Y) 
k. Serological Pipettes (Fisher, cat. #1367522, 1367520, 136682) 
l. Biohazard Waste Container 
m. Sharpie 
n. Cell Freezing Medium (90% FBS/10% DMSO) 
i. Dimethyl Sulphoxide (DMSO) (Sigma, cat. #D2650) 
o. RNAlater Solution (Ambion, cat. #AM7021) 
p. Cryopreservation container 
q. Water bath 
r. Liquid nitrogen storage 
s. Vesphene 
2. Protocol: 
a. Bring samples, PBS + 2% FBS and Lymphoprep to room temperature and mix 
each reagent by inverting 
b. Add 15mL of Lymphoprep™ to SepMate™-50mL tubes by pipetting it through 
the center hole of the SepMate ™ inserts.  Set tube aside. 
c. Gently mix blood sample by inverting up and down.  Pour blood sample into 
50mL conical tube and determine combined volume.  
d. Dilute blood sample with equal volume of PBS + 2% FBS, washing out the 
original blood tubes. Discard blood sample tubes in bleach waste container. Mix 
50ml conical tube containing blood and PBS/FBS gently by inverting.  
e. Add the diluted sample by pipetting it down the side of the SepMate™ tube. The 
sample will mix with the Lymphoprep™ above the insert. Rinse out the conical 
tube with bleach and discard. 
f. Centrifuge the SepMate™ tube at 1200 X g for 10 minutes at room temperature, 
with the brake on. 
i. Note: For samples that sit 4 to >24 hours, a centrifugation time of 20 
minutes is recommended. 
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g. Remove 1-1.5mL aliquots of plasma into 2ml cryovials. Plasma samples should 
be stored at −80°C. 
h. Quickly pour the buffy coat and remaining plasma (clear top layer) into a new 
50mL conical tube; pouring should be 2 seconds or less being careful not to allow 
blood to come up through middle hole in bottom of tube. Discard the SepMate™ 
tube. 
i. Wash enriched MNCs with PBS + 2% FBS by filling the conical tube up to the 
50mL line. Centrifuge at 500 X g for 10 minutes at room temperature, with the 
brake on (wash 1).  
j. Discard supernatant, repeat wash by resuspending pellet in 50mL PBS + 2% FBS 
and centrifuge at 500 X g for 10 minutes at room temperature, with the brake on 
(wash 2). 
k. Discard supernatant and resuspend the pellet with 10mL PBS + 2 % FBS and 
remove 5uL for a 1:5 dilution (shown below). 
l. For a 1:5 dilution, add 20uL Trypan Blue and 5uL sample for a total volume of 
25uL into one well of a 96-well plate.  Remove 10uL of mixture to put in 
Hemocytometer. Count total white blood cells in the four outer chambers and 
divide by four to get an average number of cells (#).  This number is 104 cells/mL. 
Since the dilution is 1:5, it is # X 104 X 5 cells/mL. Then to calculate the total 
number of cells, multiple these numbers by the total volume of the cell suspension 
(10mls). So, # X 104 X 5 X 10 = cells total in current 10ml volume. 
i. To count cells in a 1:2 dilution, add 10uL sample to 10uL Trypan blue in 
one well of a 96-well plate and pipette to mix. Remove 10uL of mixture to 
put in Hemocytometer. Count all four quadrants (16 squares each), add 
them together, then divide by 4 to get a #. This number is 104 cells/mL. 
Since the dilution is 1:2, it is # X 104 X 2 cells/mL. Then to calculate the 
total number of cells, multiple these numbers by the total volume of the 
cell suspension (# X 104 X 2 X 10 cells total). 
m. Bring 10ml MNCs up to 50 ml with PBS + 2% FBS by filling the conical tube up 
to the 50mL line. Centrifuge at 500 X g for 10 minutes at room temperature, with 
the brake on (wash3).  
n. Discard supernatant and resuspend pellet with 1mL cell-freezing media per 5 x 
106 to 1 X 107 cells/mL (5-10 million cells/mL) based on cell counts.  
o. Dispense 1mL per cryotube and place in cryopreservation container (Mr. Frosty) 
at -80°C allowing slow freeze. Cells should be kept a minimum of 24 hours and a 
maximum of 72 hours at -80°C. 
p. Transfer vials for long-term storage into liquid nitrogen tank. 
 
 
 
 93 
APPENDIX B: SUPPLEMENTAL RESULTS 
B.1 STUDY #2 
Table 15. Inhaled Dose of Influenza for Each Ferret from Study #2 
Run Ferret ID Treatment Inhaled Dose (TCID50) 
1 F14-007 Control 834.50 
1 F14-008 Control 760.60 
1 F14-009 Control 775.50 
1 F14-010 Control 819.90 
Average Run 1   797.63 
2 F14-011 2.5mg/kg −2hr 1102.70 
2 F14-012 2.5mg/kg −2hr 1047.10 
2 F14-015 2.5mg/kg −2hr 1047.10 
2 F14-016 2.5mg/kg −2hr 1091.70 
Average Run 2   1072.15 
3 F14-013 10mg/kg −2hr 797.80 
3 F14-014 10mg/kg −2hr 753.10 
3 F14-017 10mg/kg −2hr 730.40 
3 F14-018 10mg/kg −2hr 783.00 
Average Run 3   766.08 
    
Overall Average Inhaled Dose:   878.62 
       *Note: F14-018 died on day 2 of study #2 and was not included in data analysis 
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Table 16. Temperature (°C) of Ferrets in Study #2 
 F14-
007 
F14-
008 
F14-
009 
F14-
010 
F14-
011 
F14-
012 
F14-
015 
F14-
016 
F14-
013 
F14-
014 
F14-
017 
Day Control 2.5mg/kg HB36.6 -2hr 10mg/kg HB36.6 -2hr 
0 38.7 38.7 38.7 38.6 39.0 37.9 38.2 38.4 39.0 39.0 38.8 
1 38.9 38.3 38.6 38.7 38.7 38.5 38.9 38.7 38.7 38.7 39.4 
2 40.0 40.2 40.1 40.6 39.8 40.7 40.5 40.9 39.8 39.8 39.9 
3 38.5 39.4 38.7 38.1 39.9 38.9 39.3 39.0 39.9 39.9 39.8 
 
Table 17. Weight (kg) of Ferrets in Study #2 
 F14-
007 
F14-
008 
F14-
009 
F14-
010 
F14-
011 
F14-
012 
F14-
015 
F14-
016 
F14-
013 
F14-
014 
F14-
017 
Day Control 2.5mg/kg HB36.6 -2hr 10mg/kg HB36.6 -2hr 
0 0.86 0.76 0.78 0.84 0.75 0.7 0.7 0.74 0.81 0.75 0.72 
1 0.87 0.77 0.78 0.84 0.75 0.67 0.72 0.74 0.86 0.75 0.71 
2 0.86 0.74 0.75 0.84 0.68 0.65 0.69 0.72 0.85 0.68 0.71 
3 0.86 0.71 0.75 0.84 0.69 0.64 0.68 0.7 0.83 0.69 0.7 
 
Table 18. Weight Change (%) of Ferrets in Study #2 
 F14-
007 
F14-
008 
F14-
009 
F14-
010 
F14-
011 
F14-
012 
F14-
015 
F14-
016 
F14-
013 
F14-
014 
F14-
017 
Day Control 2.5mg/kg HB36.6 -2hr 10mg/kg HB36.6 -2hr 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1 1.16 1.32 0.00 0.00 0.00 -4.29 2.86 0.00 6.17 0.00 -1.39 
2 0.00 -2.63 -3.85 0.00 -9.33 -7.14 -1.43 -2.70 4.94 -9.33 -1.39 
3 0.00 -6.58 -3.85 0.00 -8.00 -8.57 -2.86 -5.41 2.47 -8.00 -2.78 
 
Table 19. Clinical Scores of Ferrets in Study #2 
 F14-
007 
F14-
008 
F14-
009 
F14-
010 
F14-
011 
F14-
012 
F14-
015 
F14-
016 
F14-
013 
F14-
014 
F14-
017 
Day Control 2.5mg/kg HB36.6 -2hr 10mg/kg HB36.6 -2hr 
0 0 0 0 0 0 0 0 0 0 0 0 
1 0 0 4 4 0 0 2 2 0 0 0 
2 34 38 24 24 21 21 19 24 0 21 2 
3 56 50 46 46 29 29 21 26 26 31 4 
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Table 20. Nasal Wash Viral Titers (CEID50/ml Equivalent) for Study #2 
 F14-
007 
F14-
008 
F14-
009 
F14-
010 
F14-
011 
F14-
012 
F14-
015 
F14-
016 
F14-
013 
F14-
014 
F14-
017 
Day Control 2.5mg/kg HB36.6 -2hr 10mg/kg HB36.6 -2hr 
1 5.99E
+02 
5.92E+
04 
1.51E+
04 
3.14E-
01 
1.43E+
03 
5.33E+
03 
1.30E+
03 
6.50E+
00 
1.77E+
01 
4.41E+
01 
5.83E+
02 
2 1.61E
+06 
6.66E+
05 
4.16E+
05 
4.04E+
05 
8.73E+
05 
3.48E+
05 
3.42E+
03 
3.77E+
05 
8.65E+
01 
2.23E+
05 
1.20E+
05 
3 2.97E
+04 
1.49E+
04 
1.76E+
03 
4.05E+
03 
6.33E+
04 
3.85E+
03 
8.02E+
04 
4.69E+
04 
3.16E+
05 
1.29E+
05 
1.87E+
04 
 
Table 21. Lung 4/6 Viral Titers (CEID50/ml Equivalent) for Study #2 
 F14-
007 
F14-
008 
F14-
009 
F14-
010 
F14-
011 
F14-
012 
F14-
015 
F14-
016 
F14-
013 
F14-
014 
F14-017 
Day Control 2.5mg/kg HB36.6 -2hr 10mg/kg HB36.6 -2hr 
3 3.35E
+05 
6.38E
+05 
5.21E
+04 
3.68E
+04 
6.43E
+02 
1.58E
+03 
1.27E
+04 
4.40E
+02 
4.82E
+05 
6.54E
+04 
4.55E
+04 
B.2 STUDY #3 
Table 22. Inhaled Dose of Influenza for Each Ferret from Study #3 
Run Ferret ID Treatment Inhaled Dose (TCID50) 
1 F15-003 Control 1700.50 
1 F15-006 20mg/kg -24hrs 1556.70 
1 F15-007 20mg/kg -24hrs 1474.90 
Average Run 1   1577.37 
2 F15-004 Control 2021.90 
2 F15-008 20mg/kg -24hrs 2000.50 
2 F15-009 20mg/kg -24hrs 2021.90 
Average Run 2   2014.77 
3 F15-001 20mg/kg -2hrs 1524.20 
3 F15-002 20mg/kg -2hrs 1491.40 
3 F15-005 10mg/kg -2hrs 1605.10 
Average Run 3   1540.23 
    
Overall Average Inhaled Dose:   1710.79 
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Table 23. Temperature (°C) of Ferrets in Study #3 
 F15-003 F15-004 F15-001 F15-002 F15-006 F15-007 F15-008 F15-009 
Day Control 20mg/kg HB36.6 -2hr 20mg/kg HB36.6 -24hr 
0 38.6 37.2 38.6 39.4 38.1 38.1 38.5 38.6 
1 39.7 38.7 39.3 39.9 39.1 39.3 38.7 39.6 
2 39.8 38.1 40.2 39.4 40.4 39.6 39.2 40.0 
3 38.0 37.9 38.9 39.9 40.1 39.5 38.7 Missing Data 
4 37.9 38.4 38.4 39.4 39.4 39.1 39.3 37.8 
5 37.6 38.4 39.8 38.2 40.1 40.8 38.8 38.3 
6 39.9 38.2 37.9 39.6 38.3 39.3 38.3 37.9 
 
Table 24. Weight (kg) of Ferrets in Study #3 
 F15-003 F15-004 F15-001 F15-002 F15-006 F15-007 F15-008 F15-009 
Day Control 20mg/kg HB36.6 -2hr 20mg/kg HB36.6 -24hr 
0 0.81 0.71 0.70 0.68 0.72 0.67 0.70 0.71 
1 0.79 0.68 0.72 0.70 0.73 0.65 0.68 0.71 
2 0.72 0.62 0.65 0.63 0.63 0.57 0.62 0.63 
3 0.72 0.50 0.65 0.60 0.62 0.53 0.59 0.63 
4 0.71 0.59 0.63 0.65 0.65 0.58 0.62 0.61 
5 0.70 0.58 0.64 0.62 0.64 0.56 0.60 0.61 
6 0.68 0.55 0.63 0.59 0.61 0.54 0.58 0.59 
 
Table 25. Change in Weight (%) of Ferrets in Study #3 
 F15-003 F15-004 F15-001 F15-002 F15-006 F15-007 F15-008 F15-009 
Day Control 20mg/kg HB36.6 -2hr 20mg/kg HB36.6 -24hr 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1 -2.47 -4.23 2.86 2.94 1.39 -2.99 -2.86 0.00 
2 -11.11 -12.68 -7.14 -7.35 -12.50 -14.93 -11.43 -11.27 
3 -11.11 -29.58 -7.14 -11.76 -13.89 -20.90 -15.71 -11.27 
4 -12.35 -16.90 -10.00 -4.41 -9.72 -13.43 -11.43 -14.08 
5 -13.58 -18.31 -8.57 -8.82 -11.11 -16.42 -14.29 -14.08 
6 -16.05 -22.54 -10.00 -13.24 -15.28 -19.40 -17.14 -16.90 
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Table 26. Clinical Scores of Ferrets in Study #3 
 F15-003 F15-004 F15-001 F15-002 F15-006 F15-007 F15-008 F15-009 
Day Control 20mg/kg HB36.6 -2hr 20mg/kg HB36.6 -24hr 
0 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 
2 4 7 6 13 2 4 4 4 
3 18 18 18 18 16 14 27 18 
4 36 38 33 31 21 26 16 22 
5 27 37 19 14 15 13 11 11 
6 30 38 24 9 11 13 11 16 
 
Table 27. Nasal Wash Viral Titers (CEID50/ml or TCID50/ml Equivalent) for Study #3 
 F15-003 F15-004 F15-001 F15-002 F15-006 F15-007 F15-008 F15-
009 
Day Control 20mg/kg HB36.6 -2hr 20mg/kg HB36.6 -24hr 
0 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E
+00 
1 6.83E+02 4.63E+03 2.43E+03 1.27E+03 2.46E+03 2.74E+03 2.67E+03 3.75E
+03 
2 3.04E+03 1.35E+04 2.95E+04 1.35E+04 2.85E+04 5.28E+03 3.18E+03 6.56E
+03 
3 4.23E+03 5.26E+04 5.46E+03 1.31E+05 2.08E+04 1.33E+04 1.05E+04 5.84E
+04 
4 8.55E+02 3.71E+03 1.27E+02 1.19E+03 9.97E+02 1.01E+03 4.23E+02 1.99E
+03 
5 5.00E+03 2.76E+03 5.12E+03 1.92E+04 3.07E+04 1.30E+04 2.95E+03 5.14E
+03 
6 8.15E+01 3.04E+04 7.68E+03 7.91E+02 2.51E+02 4.71E+03 2.13E+02 1.16E
+02 
 
Table 28. Lung 4/6 Viral Titers (TCID50/ml Equivalent) for Study #3 
 F15-003 F15-004 F15-001 F15-002 F15-006 F15-007 F15-008 F15-009 
Day Control 20mg/kg HB36.6 -2hr 20mg/kg HB36.6 -24hr 
6 4.08E+02 2.66E+03 1.95E+04 1.55E+03 6.37E+
04 
3.71E+
03 
7.67E+
03 
2.22E+
06 
 
 
 
 98 
B.3 STUDY #4 
Table 29. Inhaled Dose of Influenza for Each Ferret from Study #4 
Run Ferret ID Treatment Inhaled Dose (TCID50) 
1 F15-010 Control 2115.30 
1 F15-012 20mg/kg D1-5 2220.20 
1 F15-013 Tamiflu 2505.60 
Average Run 1   2280.37 
2 F15-011 Control 4048.10 
2 F15-016 Tamiflu 3687.30 
2 F15-019 20mg/kg D1-5 3451.50 
Average Run 2   3728.97 
3 F15-014 20mg/kg −2hr 3852.70 
3 F15-015 20mg/kg −2hr 3687.30 
3 F15-018 Tamiflu 3918.20 
3 F15-020 20mg/kg D1-5 3348.80 
Average Run 3   3701.75 
4 F15-017 Tamiflu 10401.10 
4 F15-021 20mg/kg D1-5 8906.80 
4 F15-022 Control 10486.70 
Average Run 4   9931.53 
    
Overall Average Inhaled Dose:   4817.66 
 
Table 30. Temperature (°C) of Ferrets in Study #4 
 F15-022 F15-014 F15-015 F15-
012 
F15-
019 
F15-
020 
F15-
021 
F15-
013 
F15-
016 
F15-
017 
F15-
018 
Day Control 20mg/kg HB36.6 -2hr 20 mg/kg HB36.6 D1-D5 5mg/kg Tamiflu D1-D5 
0 38.5 38.2 38.6 38.4 39.3 37.7 39.0 38.9 38.8 38.7 38.1 
1 38.6 38.1 38.6 39.0 37.3 38.4 37.7 39.8 38.8 39.2 38.8 
2 40.1 39.9 40.1 39.1 40.4 38.9 38.8 40.3 39.4 39.7 38.8 
3 39.7 39.4 39.1 37.4 37.9 37.6 37.6 37.3 38.3 38.3 38.8 
4 38.3 39.4 38.9 37.0 37.4 37.5 37.0 39.0 38.3 38.0 38.2 
5 39.7 38.8 39.1 39.6 39.3 39.5 38.1 39.2 37.7 38.7 39.2 
6 40.3 39.0 39.2 38.1 37.5 37.7 37.8 39.3 39.4 38.8 38.5 
7 38.4   38.7 38.4    38.7 38.4  
*Blank spaces on day 7 indicate ferret was necropsied on day 6. 
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Table 31. Weight (kg) of Ferrets in Study #4 
 F15-022 F15-014 F15-015 F15-012 F15-019 F15-020 F15-021 F15-013 F15-016 F15-017 F15-018 
Day Control 20mg/kg HB36.6 -2hr 20 mg/kg HB36.6 D1-D5 5mg/kg Tamiflu D1-D5 
0 0.92 0.88 0.83 0.80 0.76 0.73 0.74 0.94 0.83 0.91 0.90 
1 0.91 0.88 0.80 0.79 0.74 0.71 0.73 0.93 0.81 0.88 0.88 
2 0.84 0.82 0.77 0.74 0.69 0.66 0.67 0.88 0.76 0.83 0.84 
3 0.81 0.73 0.78 0.71 0.67 0.63 0.64 0.85 0.74 0.80 0.82 
4 0.78 0.75 0.71 0.69 0.65 0.61 0.62 0.84 0.78 0.77 0.82 
5 0.80 0.69 0.74 0.68 0.64 0.61 0.59 0.82 0.75 0.83 0.82 
6 0.79 0.71 0.68 0.67 0.63 0.58 0.60 0.79 0.77 0.81 0.78 
7 0.80   0.66 0.62    0.75 0.83  
*Blank spaces on day 7 indicate ferret was necropsied on day 6. 
Table 32. Weight Change (%) of Ferrets in Study #4 
 F15-022 F15-014 F15-015 F15-012 F15-019 F15-020 F15-021 F15-013 F15-016 F15-017 F15-018 
Day Control 20mg/kg HB36.6 -2hr 20 mg/kg HB36.6 D1-D5 5mg/kg Tamiflu D1-D5 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1 -1.09 0.00 -3.61 -1.25 -2.63 -2.74 -1.35 -1.06 -2.41 -3.30 -2.22 
2 -8.70 -6.82 -7.23 -7.50 -9.21 -9.59 -9.46 -6.38 -8.43 -8.79 -6.67 
3 -11.96 -17.05 -6.02 -11.25 -11.84 -13.70 -13.51 -9.57 -10.84 -12.09 -8.89 
4 -15.22 -14.77 -14.46 -13.75 -14.47 -16.44 -16.22 -10.64 -6.02 -15.38 -8.89 
5 -13.04 -21.59 -10.84 -15.00 -15.79 -16.44 -20.27 -12.77 -9.64 -8.79 -8.89 
6 -14.13 -19.32 -18.07 -16.25 -17.11 -20.55 -18.92 -15.96 -7.23 -10.99 -13.33 
7 -13.04   -17.50 -18.42    -9.64 -8.79  
*Blank spaces on day 7 indicate ferret was necropsied on day 6. 
Table 33. Clinical Scores of Ferrets in Study #4 
 F15-022 F15-014 F15-015 F15-012 F15-019 F15-020 F15-021 F15-013 F15-016 F15-017 F15-018 
Day Control 20mg/kg HB36.6 -2hr 20 mg/kg HB36.6 D1-D5 5mg/kg Tamiflu D1-D5 
0 0 0 0 0 0 0 0 0 0 0 0 
1 2 0 0 2 2 0 0 2 0 0 2 
2 38 18 28 31 41 26 48 21 33 31 38 
3 21 18 23 36 51 33 41 26 26 21 26 
4 21 23 16 31 31 46 33 28 28 28 18 
5 17 28 23 23 25 48 33 21 14 7 21 
6 21 26 24 34 36 43 43 21 7 2 26 
7 14   26 18    4 4  
*Blank spaces on day 7 indicate ferret was necropsied on day 6. 
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Table 34. Nasal Wash Viral Titers (CEID50/ml Equivalent) for Study #4 
 F15-022 F15-014 F15-015 F15-
012 
F15-
019 
F15-
020 
F15-
021 
F15-
013 
F15-
016 
F15-
017 
F15-
018 
Day Control 20mg/kg HB36.6 -2hr 20 mg/kg HB36.6 D1-D5 5mg/kg Tamiflu D1-D5 
3 1.77E+06 1.65E+06 3.08E+05 3.03E
+05 
9.55E
+05 
6.17E
+05 
1.65E
+06 
6.54E
+05 
2.02E
+06 
6.26E
+05 
2.35E
+06 
6 3.68E+05 3.76E+05 6.79E+05 3.01E
+05 
2.43E
+05 
9.37E
+05 
5.31E
+05 
7.37E
+05 
1.01E
+06 
3.33E
+05 
4.11E
+05 
 
Table 35. Lung 4/6 Viral Titers (TCID50/ml Equivalent) for Study #4 
 F15-022 F15-014 F15-015 F15-
012 
F15-
019 
F15-
020 
F15-
021 
F15-
013 
F15-
016 
F15-
017 
F15-
018 
Day Control 20mg/kg HB36.6 -2hr 20 mg/kg HB36.6 D1-D5 5mg/kg Tamiflu D1-D5 
6 1.25E+01 3.97E+04 1.61E+04 3.75E
+02 
8.79E
+02 
5.91E
+03 
2.59E
+04 
2.39E
+03 
6.44E
+02 
3.41E
+02 
2.83E
+04 
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